country,city,address_1,reason_for_recall,address_2,product_quantity,code_info,center_classification_date,distribution_pattern,state,product_description,report_date,classification,recalling_firm,recall_number,initial_firm_notification,event_id,termination_date,more_code_info,recall_initiation_date,postal_code,voluntary_mandated,status,openfda.pharm_class_cs,openfda.pharm_class_moa,openfda.pharm_class_pe,openfda.original_packager_product_ndc,application_number,brand_name,generic_name,manufacturer_name,product_ndc,route,substance_name,rxcui,spl_id,spl_set_id,package_ndc,is_original_packager,upc,nui,pharm_class_epc,unii
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
United States,Davie,4955 Orange Dr,Failed Tablet/Capsule Specifications: Recall due to complaints of split or broken tablets.,,"36,538 bottles","Lot #: 605956A, 605958A, Exp. 9/30/2014; 644678M, Exp. 10/31/2014; 661841A, Exp. 11/30/2014; 717469A, Exp 2/28/2015",20140930,Nationwide and Puerto Rico,FL,"Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75 mg/0.2 mg, 60-count bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60, UPC 3 05910 39860 6.",20141008,Class II,"Actavis Laboratories, FL, Inc.",D-1616-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",69237,20161223,,20140424,33314-3902,Voluntary: Firm Initiated,Terminated,"['Prostaglandins E, Synthetic [CS]']",,,,'ANDA201089','DICLOFENAC SODIUM AND MISOPROSTOL','DICLOFENAC SODIUM AND MISOPROSTOL',"'Actavis Pharma, Inc.'","'0591-0397', '0591-0398'",'ORAL',"'DICLOFENAC SODIUM', 'MISOPROSTOL'","'857706', '1359105'",'f2fd7c9c-f7b8-4836-9e3f-ba215efe19c9','df8b8660-0c24-4848-8bea-c1b935090c66',"'0591-0397-19', '0591-0397-60', '0591-0398-60'",True,"'0305910397609', '0305910398606', '305910398606'","'N0000175785', 'M0017811'",'Prostaglandin E1 Analog EPC',"'0E43V0BB57', 'QTG126297Q'"
United States,Lake Forest,275 N Field Dr,Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.,,"72,300 vials","Lot: 23-505-EV, Exp. 11/14",20130828,Nationwide and Puerto Rico,IL,"Diazepam Injection, USP, 5 mg/mL, 10 mL, Multiple-dose Sterile Non-pyrogenic, Fliptop Vial, C-IV, Rx Only, Hospira, Inc., Lake Forest, IL 60045, USA,  NDC 0409-3213-12",20130904,Class II,Hospira Inc.,D-927-2013,Letter,66104,20141028,,20130816,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA071583','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-3213',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','309845','9079d34b-061e-49db-8e30-7a788bcbafa6','7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f',"'0409-3213-11', '0409-3213-12'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Hawthorne,3 Skyline Dr,Failed Content Uniformity Specifications.,,1396 Bottles,"Lot #: 149400, Expiry: January 2016;   Lot #: 149649, Expiry: January 2016.",20140912,"United States including: OH, HI, NH, MS, IL, TX, CA.",NY,"Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd.,  Haifa Bay, Israel 26110.  Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.",20140924,Class III,"Taro Pharmaceuticals U.S.A., Inc.",D-1584-2014,Letter,69075,20180518,,20140825,10532-2174,Voluntary: Firm initiated,Terminated,,,,,'ANDA040301','WARFARIN SODIUM','WARFARIN SODIUM',"'Taro Pharmaceuticals U.S.A., Inc.'","'51672-4027', '51672-4028', '51672-4029', '51672-4030', '51672-4031', '51672-4032', '51672-4033', '51672-4034', '51672-4035'",'ORAL','WARFARIN SODIUM',"'855288', '855296', '855302', '855312', '855318', '855324', '855332', '855338', '855344'",'23995412-b23d-4ea0-96df-f1b31ce4f024','8ad881e0-ca41-42ad-9d7d-eb85b3a30af0',"'51672-4027-1', '51672-4027-3', '51672-4027-7', '51672-4027-0', '51672-4028-1', '51672-4028-3', '51672-4028-7', '51672-4028-0', '51672-4029-1', '51672-4029-3', '51672-4029-7', '51672-4029-0', '51672-4030-1', '51672-4030-3', '51672-4030-7', '51672-4030-0', '51672-4031-1', '51672-4031-3', '51672-4031-7', '51672-4031-0', '51672-4032-1', '51672-4032-3', '51672-4032-7', '51672-4032-0', '51672-4033-1', '51672-4033-3', '51672-4033-7', '51672-4033-0', '51672-4034-1', '51672-4034-3', '51672-4034-0', '51672-4035-1', '51672-4035-3', '51672-4035-0'",True,"'0351672403119', '0351672403010', '0351672403218', '0351672402914', '0351672402815', '0351672403416', '0351672403515', '0351672403317'",nan,nan,'6153CWM0CL'
United States,Bridgewater,400 Somerset Corporate Blvd,Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.,,22 bottles,"Lots: a)18J020P, Exp 08/2020; b) 18J034P, Exp 08/2020",20190214,Nationwide in the USA and Puerto Rico,NJ,"Cardizem CD (diltiazem HCl) capsules, 300 mg, packaged in a) 30-count bottles (NDC 0187-0798-30); and b) 90-count bottles (NDC 0187-0798-42), Rx Only, Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7, Canada.",20190220,Class III,Valeant Pharmaceuticals North America LLC,D-0490-2019,Letter,82021,20200708,,20190130,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA020062','CARDIZEM CD','DILTIAZEM HYDROCHLORIDE','Bausch Health US LLC',"'0187-0795', '0187-0796', '0187-0797', '0187-0798', '0187-0799'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830798', '830801', '830803', '830837', '830839', '830845', '830847', '830861', '830863'",'2329929b-21b6-49a4-be2b-4d2026c732d8','1042fa13-e6af-46b9-8008-6c941f0978b1',"'0187-0795-30', '0187-0795-42', '0187-0795-49', '0187-0796-30', '0187-0796-42', '0187-0796-49', '0187-0796-50', '0187-0797-30', '0187-0797-42', '0187-0797-49', '0187-0798-30', '0187-0798-42', '0187-0799-42'",True,nan,nan,nan,'OLH94387TE'
United States,Princeton,107 College Rd E,Failed dissolution specifications - low dissolution  results at S3 stage.,,12132 cartons,"Lot # KB50877, KB50878, Exp 11/17; KB50878, 01KB60251, Exp 3/18",20170302,U.S. Nationwide,NJ,"Zenatane (isotretinoin) capsules, 20 mg, packaged in 30-count  cartons (3 x 10 blister cards), Rx Only, Manufactured By:Cipla Limited Kurkumbh Village Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090  India, NDC 55111-136-81",20170308,Class III,"Dr. Reddy's Laboratories, Inc.",D-0507-2017,Letter,76539,20181219,,20170215,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Sellersville,650 Cathill Rd,Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing,,"47,200 blister packs","NDC 0555-9028-58, Lot numbers 33802123A, exp 4/2013; 33802202A, exp 5/2013; 33802203A, exp 5/2013; and 33802204A, exp 5/2013.",20130705,Nationwide distribution.  No foreign or government accounts.,PA,"Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58",20130717,Class III,"Teva Pharmaceuticals USA, Inc.",D-682-2013,Letter,64644,20140410,,20130315,18960-1512,Voluntary: Firm initiated,Terminated,,['Estrogen Receptor Agonists [MoA]'],,,'ANDA076380','JUNEL','NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL',"'Teva Pharmaceuticals USA, Inc.'","'0555-9025', '0555-9026', '0555-9027', '0555-9028'",'ORAL',"'NORETHINDRONE ACETATE', 'ETHINYL ESTRADIOL'","'259176', '1358762', '1358763', '1358765', '1358776', '1358780', '1359022', '1359023', '1359025', '1359028', '1359030'",'9fd530a8-adc6-4bc2-b5d8-3d9b51be9a59','8b82ad14-580c-4145-b825-dce849f95363',"'0555-9025-42', '0555-9026-58', '0555-9027-42', '0555-9028-58'",True,nan,"'N0000175825', 'N0000000100'",'Estrogen EPC',"'9S44LIC7OJ', '423D2T571U'"
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"117,600 patches","Lot #70132, Exp. 09/14",20140320,Nationwide.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3.",20140326,Class II,"Noven Pharmaceuticals, Inc.",D-1172-2014,Letter,67718,20190319,,20140213,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lexington,300-400 Shire Way,Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.,,8359 vials,"US: Lot #:  FEW13-001, FEW13-002, FED13-006; Expiry: 10/15.  Mexico: Lot #: FED 013-010; Expiry: 10/15.  Columbia: Lot #: FED 013-011; Expiry: 10/15.",20140418,"US Nationwide including Puerto Rico; Mexico, Columbia",MA,"VPRIVÂ¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.",20140430,Class I,"Shire Human Genetic Therapies, Inc.",D-1251-2014,Letter,67690,20160831,,20140314,02421-2101,Voluntary: Firm initiated,Terminated,,,,,'BLA022575','VPRIV','VELAGLUCERASE ALFA',"'Takeda Pharmaceuticals America, Inc.'",'54092-701','INTRAVENOUS','VELAGLUCERASE ALFA',"'901808', '901812'",'36373dc0-e72a-43c6-bdef-03025667e3a9','ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf','54092-701-04',True,nan,'N0000175820','Hydrolytic Lysosomal Glucocerebroside-specific Enzyme EPC','23HYE36B0I'
United States,Jersey City,Harborside Financial Center,Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets,Plaza V- Suite 1900,"40,621 blister packs","Lots W00733 and W00946, exp Apr 2019",20170531,Nationwide,NJ,"Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06",20170607,Class II,"Forest Laboratories, LLC",D-0880-2017,Letter,77315,20181115,,20170518,07311,Voluntary: Firm initiated,Terminated,,,,,'NDA022117','SAPHRIS','ASENAPINE MALEATE',"'Allergan, Inc.'","'0456-2402', '0456-2405', '0456-2410'",'SUBLINGUAL','ASENAPINE MALEATE',"'859975', '859979', '859981', '859983', '1606337', '1606490'",'5d023cc1-46bb-4846-99f1-fa5d0a547bee','5429f134-839f-4ffc-9944-55f51238def8',"'0456-2402-10', '0456-2402-06', '0456-2402-60', '0456-2402-11', '0456-2402-63', '0456-2405-10', '0456-2405-06', '0456-2405-60', '0456-2405-11', '0456-2405-63', '0456-2410-10', '0456-2410-06', '0456-2410-60', '0456-2410-11', '0456-2410-63'",True,nan,nan,nan,'CU9463U2E2'
United States,Louisville,416 S Taylor Ave,"Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the  printed carton are labeled appropriately as Articadent DENTAL.",,240 cartons of 50 glass cartridges each,"Lot # D02599A, exp. Sept 2020, D02608B, exp. October 2020",20190528,Nationwide in the USA,CO,"Articaine DENTAL, Articane hydrochloride 4% and epinephrine 1:100,000,   50 cartridges. 1.7 mL each, Rx only, Manufactured for: DENTSPLY Pharmaceutical, by Novocol Pharmaceutical of Canada, Inc. York, PA 17404, NDC 66312-601-16 Reorder #: 51116",20190529,Class II,Septodont Inc.,D-1307-2019,Letter,82760,20201119,,20190502,80027-3028,Voluntary: Firm initiated,Terminated,,,,,'NDA020971','ARTICADENT','ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE','Dentsply Pharmaceutical',"'66312-601', '66312-602'",'SUBCUTANEOUS',"'ARTICAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'","'1011646', '1011648', '1595029', '1595035'",'9bc537d4-9261-4276-9cad-bc1b10faabf2','9ca8fb43-4f34-47c0-8b79-3b5bd1eaee00',"'66312-601-16', '66312-602-16'",True,'0000004235644',nan,nan,"'30Q7KI53AK', 'QS9014Q792'"
United States,East Windsor,279 Princeton Hightstown Rd,"CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.",,"134,160 bottles",RA3018001-A Jul 2020  RA3018002-A Jul-2020  RA3018003-A Jul 2020  RA3018004-A Aug 2020  RA3018005-A Aug 2020  RA3018006-A Aug 2020  RA3018007-A Sep 2020  RA3018008-A  Sep 2020  RA3018009-A Sep 2020  RA3018010-A Oct 2020  RA3019001-A Jan 2021  RA3019002-A Jan 2021  RA3019003-A May 2021,20191126,nationwide,NJ,"Aurobindo Ranitidine Capsules 300 mg, 30-count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520  NDC 59651-145-30",20191204,Class II,AuroMedics Pharma LLC,D-0528-2020,Press Release,84218,,,20191106,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA211058','RANITIDINE','RANITIDINE','Aurobindo Pharma Limited',"'59651-144', '59651-145'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198190', '198192'",'80acf18a-fb08-4139-b048-eac4d14bd906','e2061ebe-29df-442f-bd4a-6bfa4c148ffe',"'59651-144-60', '59651-144-05', '59651-145-30'",True,nan,nan,nan,'BK76465IHM'
United States,Bridgewater,55 Corporate Dr,Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.,,422 vials,"Lot #: K5006Y02, Exp 31AUG18",20171030,Nationwide in the USA,NJ,"Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.",20171108,Class III,Sanofi-Aventis U.S. LLC,D-0056-2018,Letter,78232,20200513,,20171013,08807-1265,Voluntary: Firm initiated,Terminated,,['Nucleic Acid Synthesis Inhibitors [MoA]'],,,'NDA021673','CLOFARABINE','CLOFARABINE','Winthrop U.S.','0955-1746','INTRAVENOUS','CLOFARABINE','486419','7884f725-26dc-4c9e-b290-a440d047a547','7912ab7f-efe0-460c-9eb9-7d2c7d37548a','0955-1746-01',True,nan,"'N0000000233', 'N0000175595'",'Nucleoside Metabolic Inhibitor EPC','762RDY0Y2H'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,68 bottles,Lot NVWG Exp - 11/30/2016,20140731,Nationwide,NJ,"Welchol Tablets (colesevelam HCl) 625 mg, 180 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 ---NDC 65597-701-18",20140806,Class II,Daiichi Sankyo Pharma Development,D-1505-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,,,,,'NDA021176','WELCHOL','COLESEVELAM HYDROCHLORIDE','Daiichi Sankyo Inc.',"'65597-701', '65597-902'",'ORAL','COLESEVELAM HYDROCHLORIDE',"'866905', '866907', '866910', '866912'",'266a7143-c10d-40ee-b217-e565db2295b7','4a06d3b2-7229-4398-baba-5d0a72f63821',"'65597-701-18', '65597-902-30'",True,'0365597902305',nan,nan,'P4SG24WI5Q'
United States,Pennington,73 Route 31 N,Failed Dissolution Specifications; 6 month time point,,"16,356 bottles","a) MS1667 exp 01/2018; M601708, exp 03/2018;       b) MS1667, MS1668, MS1669, exp 01/2018; M601515, M601516, exp 03/2018; M602920, M602921, M605399, M602937, M602938, M602939, exp 04/2018; M603988, exp 06/2018",20161220,Nationwide,NJ,"BuPROPion Hydrochloride Extended-Release Tablets (XL),  300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and  b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534",20161228,Class III,Zydus Pharmaceuticals USA Inc,D-0207-2017,Letter,75764,20200723,,20161102,08534-3601,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','Zydus Pharmaceuticals (USA) Inc.',"'68382-353', '68382-354'",'ORAL','BUPROPION HYDROCHLORIDE',"'993541', '993557'",'3a335702-b823-4e62-abba-f7743c3c1b51','8d937ca3-3351-40f1-8192-348ba0c68162',"'68382-354-06', '68382-354-16', '68382-354-05', '68382-354-10', '68382-353-06', '68382-353-16', '68382-353-05', '68382-353-10'",True,'0368382353054',nan,nan,'ZG7E5POY8O'
India,"Jadcherla Mandal, Mahaboob Nagar",Unit V (SEZ Unit I in APIIC SEZ),CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.,"Surv. No. 439-441, 458, Polepally Vill.","441,408 bottles",All Lots with expiration dates 7/2018 to 6/2020,20180823,Nationwide,,"Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only   Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854   By: Hetero Hetero Labs Limited, Unit V, Pollepally  Jadcherla Mahabubnagar - 509-301, India.   NDC 31722-747-90  UPC 331722747905",20180829,Class II,Hetero Labs Limited Unit V,D-1115-2018,Letter,80773,,,20180808,,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA203311','VALSARTAN','VALSARTAN',"'Camber Pharmaceuticals, Inc.'","'31722-745', '31722-746', '31722-747', '31722-748'",'ORAL','VALSARTAN',"'349199', '349200', '349201', '349483'",'222acee8-e4e7-4ed3-8965-47a1cde2298c','0ff36e83-b307-42db-a2ab-bae3f6805c20',"'31722-745-30', '31722-745-90', '31722-745-05', '31722-745-31', '31722-745-32', '31722-746-30', '31722-746-90', '31722-746-05', '31722-746-31', '31722-746-32', '31722-747-30', '31722-747-90', '31722-747-05', '31722-747-31', '31722-747-32', '31722-748-30', '31722-748-90', '31722-748-05', '31722-748-31', '31722-748-32', '3317227479'",True,'331722747905',"'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC','80M03YXJ7I'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: C238 BUD: 11/14/2018,20181107,Nationwide.,OK,"Estradiol 25mg pellet, 1 count (NDC 69761-025-01), 6 count (NDC 69761-025-06), 12 count (NDC 69761-025-12), and 30 count (NDC 69761-025-30) vials, Rx Only, Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0229-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-025','ORAL','ESTRADIOL',nan,'d0c7055e-aa47-4b03-b918-d1edae2bd0bc','f5823883-cbfd-422a-96a9-67ac6ea81c23',"'69761-025-12', '69761-025-30', '69761-025-01', '69761-025-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Tampa,8500 Hidden River Pkwy,Labeling: Incorrect or Missing Package Insert: Package insert is missing updates compared with reference drug insert.,,"119,393 Bottles","Lot #:199001, Expiry: 01/2016; Lot #: 222591, Expiry: 04/2016; Lot #: 224491, Expiry: 06/2016; Lot #: 229241, Expiry: 08/2016; Lot #: 232941, Expiry: 11/2016; Lot #: 239921, Expiry: 02/2017; Lot #: 241701, Expiry: 04/2017; Lot #: 246851, Expiry: 07/2017.",20160128,U.S. Nationwide including Puerto Rico.,FL,"Tropicamide Ophthalmic Solution USP, 0.5%, Packaged in 15 mL Bottles, Rx Only. Bausch and Lomb Incorporated, Tampa, FL, 33637. NDC: 24208-590-64.",20160203,Class III,"Bausch & Lomb, Inc.",D-0646-2016,Letter,73032,20200106,,20160118,33637-1014,Voluntary: Firm initiated,Terminated,,['Cholinergic Antagonists [MoA]'],,,'ANDA040064','TROPICAMIDE','TROPICAMIDE','Bausch & Lomb Incorporated',"'24208-585', '24208-590'",'OPHTHALMIC','TROPICAMIDE',"'313521', '314238'",'3f2f0e6a-c47b-4e2d-858e-3ea68d5a270e','892b78c8-36bc-47d3-850e-502899b48fb9',"'24208-590-64', '24208-585-59', '24208-585-64'",True,nan,"'N0000175574', 'N0000175370'",'Anticholinergic EPC','N0A3Z5XTC6'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"29106 bottles (2,619,540 tablets)",BLL801A Dec-19  BLL802A Dec-19  BLL803A Dec-19,20190709,Nationwide,NJ,"Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA     NDC 33342-051-10",20190717,Class II,Macleods Pharma Usa Inc,D-1460-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA202289','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Macleods Pharmaceuticals Limited',"'33342-050', '33342-051', '33342-052'",'ORAL',"'LOSARTAN POTASSIUM', 'HYDROCHLOROTHIAZIDE'","'979464', '979468', '979471'",'d5579695-0912-403b-9a85-33522bc98112','a04b5622-2c49-4d61-92b1-5dc523af7a24',"'33342-050-07', '33342-050-10', '33342-050-44', '33342-050-12', '33342-051-07', '33342-051-10', '33342-051-44', '33342-051-12', '33342-052-07', '33342-052-10', '33342-052-44', '33342-052-12'",True,"'0333342051448', '0333342051103', '0333342051073', '0333342052445', '0333342050441', '0333342052100', '0333342050106', '0333342050076', '0333342052070'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"2,455 vials","Lot #: 7801221, 7801222, Exp 03/16",20150814,Nationwide and Puerto Rico,IL,"Gemcitabine for Injection, USP, 2 g*/vial, Lyophilized powder in a Single-Use Vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, Made in India, NDC 67457-463-02, UPC 3 67457 46302 5.",20150826,Class I,Mylan Institutional LLC,D-1333-2015,Letter,71004,20160520,,20150323,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA200145','GEMCITABINE HYDROCHLORIDE','GEMCITABINE HYDROCHLORIDE','Mylan Institutional LLC',"'67457-462', '67457-464', '67457-463'",'INTRAVENOUS','GEMCITABINE HYDROCHLORIDE',"'1719000', '1719003', '1719005'",'7904b337-7a91-46e2-9cb2-c73f1f2b36bd','fdf52dca-732c-4a1a-9475-e9e1e3af4ce8',"'67457-464-20', '67457-462-01', '67457-463-02'",True,"'0367457463025', '0367457462011', '367457463025'",nan,nan,'U347PV74IL'
United States,Edmond,14844 Bristol Park Blvd,Lack of Assurance of Sterility,,,Lots: D007 BUD: 01/09/2019; D060 BUD: 3/14/2019,20181107,Nationwide.,OK,"Estradiol 6 mg pellet, 1 count (NDC 69761-006-01), 6 count (NDC 69761-006-06), 12 count (NDC 69761-006-12), and 30 count (NDC 69761-006-30) vials, Rx Only Qualgen, LLC, Edmond, OK 73013",20181114,Class II,"Qualgen, LLC",D-0230-2019,Letter,81346,20200604,,20181017,73013-1891,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,nan,'ESTRADIOL','ESTRADIOL','Qualgen LLC','69761-006','ORAL','ESTRADIOL',nan,'abe65034-0a2d-4a1f-8452-25f211563f2f','1536dc3b-ec2a-40a8-90b6-42e1d4f5326b',"'69761-006-12', '69761-006-30', '69761-006-01', '69761-006-06'",True,nan,"'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,New York,235 E 42nd St,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,,53600 vials,"Lots # 691853F, EXP. 9/1/2018; 700753F, EXP. 10/1/2018.",20180314,Nationwide in the USA,NY,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",20180321,Class I,Pfizer Inc.,D-0596-2018,Letter,79114,20190807,,20180207,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'ANDA078591','HYDROMORPHONE HYDROCHLORIDE','HYDROMORPHONE HYDROCHLORIDE',"'Teva Parenteral Medicines, Inc.'","'0703-0018', '0703-0110', '0703-0113'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'HYDROMORPHONE HYDROCHLORIDE',"'1724338', '1724340', '1724341'",'8a6499c7-a970-4743-8500-875b8104f5ba','f0b78db9-a38c-41bb-8233-5e93f7f18c5c',"'0703-0110-01', '0703-0110-03', '0703-0113-01', '0703-0113-03', '0703-0018-01'",True,nan,nan,nan,'L960UP2KRW'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"28,938  units","Lot #: 03215042A, Exp. 08/17.",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",20170329,Class III,Pfizer Inc,D-0607-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Columbus,2550 John Glenn Ave Ste A,CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.,,270 cartons,"Lot #: 174096, Exp 05/31/19",20180313,Nationwide in the USA,OH,"Aripiprazole Tablets, USP, 10 mg, 100 Tablets (10 x 10) unit dose blisters [NDC60687-179-11; UPC (01) 003 60687 179 11 7] per carton (NDC 60687-179-01), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217.",20180221,Class II,AMERICAN HEALTH PACKAGING,D-0595-2018,Letter,79036,20190314,,20180119,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['31722-819', '31722-820', '31722-827', '31722-828', '31722-829', '31722-830']",'ANDA205064','ARIPIPRAZOLE','ARIPIPRAZOLE','American Health Packaging',"'60687-157', '60687-168', '60687-179', '60687-191', '60687-202', '60687-213'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'945909e4-ab4a-3eb9-e053-2995a90ae93f','80e079f0-faf5-4c0c-b1a8-9bc3cc2cde00',"'60687-157-11', '60687-157-21', '60687-168-11', '60687-168-01', '60687-179-11', '60687-179-01', '60687-191-11', '60687-191-21', '60687-202-11', '60687-202-21', '60687-213-11', '60687-213-21'",nan,'003606871791','N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,"11,123 bottles","Lot #s: C404440, Exp 04/2016; C404946, Exp 05/2016; C505704, Exp 07/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 4 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-665-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0721-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Rockford,4901 Hiawatha Dr,Presence of Particulate Matter,,"a) 15,095 vials  b) 300 vials","Lot #: a) 7801082, Exp. 07/15 and b) 7801421, Exp. 09/16",20150813,Nationwide and Puerto Rico,IL,"Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY  10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL  61103, NDC 67457-467-99.",20150819,Class I,Mylan Institutional LLC,D-1328-2015,Letter,70936,20160629,,20150318,61103-1287,Voluntary: Firm initiated,Terminated,,,,,'ANDA201529','METHOTREXATE','METHOTREXATE','Mylan Institutional LLC',"'67457-466', '67457-467', '67457-486', '67457-485', '67457-480'","'INTRA-ARTERIAL', 'INTRAMUSCULAR', 'INTRATHECAL', 'INTRAVENOUS'",'METHOTREXATE SODIUM',"'1655956', '1655959', '1655960', '1655967', '1655968'",'6c8884a0-d167-48a8-a890-7bf72054d72b','ade151b9-b433-47dc-90f5-f6463f70c2fd',"'67457-467-21', '67457-467-99', '67457-486-04', '67457-486-99', '67457-485-08', '67457-485-99', '67457-466-10', '67457-480-40', '0069-0146-01'",True,nan,nan,nan,'3IG1E710ZN'
United States,Eatontown,465 Industrial Way W,Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.,,"a) 308,275 vials; b) 2,008,850 vials","Lot #s: a) 113153.1, 113154.1, 113155.1, Exp 05/13; 113248.1, Exp 07/13; b) 103196.1, 103197.1, 103197.2, 103198.1, Exp 07/12; 103317.1, 103318.1, 103319.1, 103345.1, 103345.2, Exp 11/12; 103346.1, 103347.1, 103348.1, 103349.1, 103350.1, Exp 12/12; 113030.1, 113031.1, 113032.1, 113033.1, 113034.1, 113035.1, 113036.1, Exp 01/13; 113245.1, 113246.1, 113247.1, Exp 07/13",20120802,All lots were distributed throughout the US.,NJ,"Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ  07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).",20120808,Class II,West-ward Pharmaceutical Corp.,D-1437-2012,Letter,62627,20150116,,20120413,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA078765','FOSPHENYTOIN SODIUM','FOSPHENYTOIN SODIUM','West-Ward Pharmaceuticals Corp',"'0143-9782', '0143-9788'","'INTRAMUSCULAR', 'INTRAVENOUS'",'FOSPHENYTOIN SODIUM',"'1670195', '1670200'",'6b56fe59-9fb1-410b-b57c-7ada1662136a','c92df63b-5140-4213-8d43-8327ff6230b7',"'0143-9788-01', '0143-9788-25', '0143-9782-01', '0143-9782-10', '0143-9704-25'",True,nan,nan,nan,'7VLR55452Z'
United States,Lake Forest,275 N Field Dr,"Lack of Assurance of Sterility: Hospira, Inc is voluntarily recalling the products due to possible leaking bags.",,"2,137,660 units","Lot #: a) 89-135-JT,  04-224-JT, 07-138-JT, Exp 4/13, 08-160-JT Exp. 8/13 ; b) 08-163-JT, 90-036-JT, 02-048-JT, Exp 2/13; c) 93-102-JT, 11-063-JT, Exp 9/12; d) 93-096-JT, Exp 11/12",20130621,"Nationwide Puerto Rico, U.S. Virgin Island, Libya, Saudi Arabia",IL,"0.9% Sodium Chloride Injection, USP, Polyolefin Flexible Container, a) 500 mL (NDC 0409-7983-30), b) 1000 mL (NDC 0409-7983-48), c) 250 mL (NDC 0409-7983-02), d) 150 mL (NDC 0409-7983-61), Rx Only, by Hospira, Inc., Lake Forest, IL 60045",20130703,Class II,Hospira Inc.,D-611-2013,Letter,61918,20150717,,20120504,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016366','SODIUM CHLORIDE','SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7983', '0409-7730', '0409-7984', '0409-7985'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807547', '1807550', '1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'9788db74-ff4f-41d6-9c2e-f8d4850e5662','089fc1de-00ae-41b6-7c97-1217f0cecc03',"'0409-7730-20', '0409-7730-36', '0409-7730-37', '0409-7983-61', '0409-7983-02', '0409-7983-03', '0409-7983-09', '0409-7983-55', '0409-7983-53', '0409-7984-37', '0409-7984-20', '0409-7984-13', '0409-7984-23', '0409-7984-36', '0409-7985-02', '0409-7985-03', '0409-7985-09', '0409-7983-30', '0409-7983-48'",True,nan,nan,nan,'451W47IQ8X'
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3697 bottles,CLO17014A exp 12/2019  CLO17015A exp 01/2020  CLO17016A exp 01/2020  CLO17017A exp 01/2020  CLO18001A exp 01/2020  CLO18002B exp 01/2020,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 100 mg 1000 film coated tablets Rx only     Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-646-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1290-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Davie,4131 Sw 47th Ave,CGMP Deviations: Recall initiated as a precautionary measure due to a potential risk of product contamination with the bacteria B. cepacia.,Suite 1403,"5,928 bottles","Lot #: 25291601, Exp 03/18",20160927,Nationwide,FL,"Ninjacof (chlophedianol HCl and pyrilamine maleate) Liquid, 12.5 mg/12.5 mg in each 5 mL, 16 fl oz (473 mL) bottle, Manufactured for: Centurion Labs, LLC, Birmingham, AL  35243, NDC 23359-032-16.",20161005,Class II,Pharmatech LLC,D-1521-2016,Letter,74874,,,20160808,33314-4026,Voluntary: Firm initiated,Ongoing,,,,,'part341','NINJACOF','CHLOPHEDIANOL HCL AND PYRILAMINE MALEATE',"'Centurion Labs, LLC'",'23359-032','ORAL',"'CHLOPHEDIANOL HYDROCHLORIDE', 'PYRILAMINE MALEATE'","'1593749', '1593756'",'b686f7d7-8d48-6b7e-e053-2a95a90a251c','e2bca40f-9c27-ec8b-2ff0-ef9847ba2037',"'23359-032-16', '23359-032-10', '23359-032-04'",True,nan,nan,nan,"'69QQ58998Y', 'R35D29L3ZA'"
United States,Largo,7265 Ulmerton Rd,CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.,,"12,059 unit  dose cups","Lot No. 428700 (Exp. 11/17), 409500 (Exp. 06/17)",20170202,Nationwide,FL,"Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case., Rx only, Manufactured by VistaPharm, Largo, FL 33771, NDC No. 66689-036-50.",20170208,Class II,"VistaPharm, Inc.",D-0460-2017,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",75650,,,20170118,33771-4809,Voluntary: Firm initiated,Ongoing,,"['Cytochrome P450 1A2 Inducers [MoA]', 'Cytochrome P450 2B6 Inducers [MoA]', 'Cytochrome P450 2C8 Inducers [MoA]', 'Cytochrome P450 2C19 Inducers [MoA]', 'Cytochrome P450 2D6 Inducers [MoA]', 'Cytochrome P450 3A Inducers [MoA]', 'Cytochrome P450 2C9 Inducers [MoA]']",['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA040342','PHENYTOIN','PHENYTOIN',"'VistaPharm, Inc.'",'66689-036','ORAL','PHENYTOIN','1313112','5bc3dfe8-2676-4ca6-b6f4-902c6dac168a','85cc5cd9-695f-4a71-9275-e0099c505185',"'66689-036-01', '66689-036-50'",True,nan,"'N0000175753', 'N0000008486', 'N0000191266', 'N0000187064', 'N0000187063', 'N0000185607', 'N0000191267', 'N0000190118', 'N0000185507'",'Anti-epileptic Agent EPC','6158TKW0C5'
United States,Peapack,100 North Route 206,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,,"11,862 units","Lot #: 03216026A, Exp. 02/18",20170322,Nationwide within US,NJ,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017  Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",20170329,Class III,Pfizer Inc,D-0608-2017,Letter,76663,20190531,,20170307,07977,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA)  in the finished product above the interim acceptable daily intake level.",,"172,296 bottles","Count, lots, expiry: [30-count bottle] Lot BEF8D058,exp 11/30/2020 [90-count bottle] Lots BEF8D009, BEF8D010, BEF8D011, BEF8D012, BEF8D013,   BEF8D007, BEF8D008, exp 3/31/2020; Lots BEF8D023, BEF8D024, BEF8D025, BEF8D020, BEF8D021, BEF8D022, exp 4/30/2020; Lots BEF8D054, BEF8D055, BEF8D056, exp 10/31/2020; Lots BEF8D057, exp 11/30/2020",20190410,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/12.5mg,  a) 30-count (NDC: 13668-117-30), b) 90-count (NDC: 13668-117-90) per bottle , Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India.  For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridge, NJ",20190417,Class II,Torrent Pharma Inc.,D-1118-2019,Letter,82585,,,20190228,07920-3856,Voluntary: Firm initiated,Ongoing,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'ANDA090528','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE','Torrent Pharmaceuticals Limited',"'13668-116', '13668-117', '13668-118'",'ORAL',"'HYDROCHLOROTHIAZIDE', 'LOSARTAN POTASSIUM'","'979464', '979468', '979471'",'456b139b-951b-41ae-8af0-7b14797427db','bbd3ab1d-0b54-4051-9fb6-a3fc0ef3d4a5',"'13668-116-90', '13668-116-10', '13668-116-74', '13668-116-30', '13668-117-30', '13668-117-90', '13668-117-10', '13668-117-74', '13668-118-30', '13668-118-90', '13668-118-10', '13668-118-74'",True,'0000787000071',"'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'3ST302B24A', '0J48LPH2TH'"
United States,Jacksonville,4345 Southpoint Blvd,"Temperature Abuse: One shipment was inadvertantly stored refrigerated rather than the labeled room temperature recommendation at McKesson Medical-Surgical Inc., one of the distributing wholesalers.",,10 vials,"Lot #140502, Exp 10/31/2015",20141003,"McKesson Medical-Surgical Inc distributed to (6) physicians and/or medical facilities in WA, OR, and MT.",FL,"Amiodarone HCl Injection, 450 mg/9 mL (50 mg per mL), 9 mL Single-Use Vial, Rx only, Manufactured for Mylan Institutional, LLC, Rockford, IL 61103, NDC 67457-153-09.",20141015,Class II,Mckesson,D-0005-2015,Telephone,69346,20170417,,20140912,32216-6166,Voluntary: Firm initiated,Terminated,,,,,'ANDA076217','AMIODARONE HYDROCHLORIDE','AMIODARONE HYDROCHLORIDE','Mylan Institutional LLC','67457-153','INTRAVENOUS','AMIODARONE HYDROCHLORIDE',"'1663224', '1663244', '1663248'",'bd9c578c-322f-41fc-936d-bf9b551a2782','fcc8658c-761a-443f-8c32-1499d86028ec',"'67457-153-00', '67457-153-03', '67457-153-99', '67457-153-09', '67457-153-18'",True,nan,nan,nan,'976728SY6Z'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3140 syringes,"Lots: L159A, Exp. 06/2021; L169A, Exp. 07/2021",20191009,Nationwide in the USA,NJ,"Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27.",20191016,Class III,GUERBET LLC,D-0138-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,,,,'NDA021569','SODIUM CHLORIDE','SODIUM CHLORIDE','Liebel-Flarsheim Company LLC','0019-1188','INTRAVASCULAR','SODIUM CHLORIDE',nan,'24d68ce2-7a7c-4927-94d1-f23106601b6f','e4540d03-06b4-4b4d-b859-75c13e5c20dd',"'0019-1188-81', '0019-1188-27'",True,'0300191188816',nan,nan,'451W47IQ8X'
United States,Huntsville,120 Vintage Dr NE,Failed Tablet/Capsule Specifications: Broken tablets found in sealed bottles.,,"23,544 bottles","T062A14A, Exp 12/15",20140903,Nationwide,AL,"OXYCODONE and ACETAMINOPHEN, USP 10 mg/325 mg, CII, 100 TABLETS, Rx only, Manufactured for: QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811, NDC 0603-4982-21",20140910,Class II,Qualitest Pharmaceuticals,D-1572-2014,Letter,69157,20160201,,20140827,35811-8216,Voluntary: Firm initiated,Terminated,,,,,'ANDA090734','OXYCODONE AND ACETAMINOPHEN','OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN','Par Pharmaceutical',"'0603-4979', '0603-4982'",'ORAL',"'OXYCODONE HYDROCHLORIDE', 'ACETAMINOPHEN'","'1049214', '1049225'",'ff6eeb3d-3d05-4f53-b33d-5eca28ff4108','c2520a5a-ef9c-47d0-82e7-12f2b23e154b',"'0603-4979-21', '0603-4979-28', '0603-4982-21', '0603-4982-28'",True,"'0306034979214', '0349884123451', '0306034982214'",nan,nan,"'362O9ITL9D', 'C1ENJ2TE6C'"
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","21,584,100 tablets","Lot #: HK6001, HK6002, HK6003, HK6004, HK6005, HK6006, HK6007, HK6008, HK6009, HK6010, HK6011, HK6012, HK6013, HK6014, HK6015, Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 400 mg, 6 x 3500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-121-29.",20180131,Class II,Marksans Pharma Inc.,D-0238-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bridgewater,400 Somerset Corporate Blvd,"Subpotent Drug; for the active, HCB, and preservatives, Propylparaben and Butylparaben at the 18 month stability test point",,1663 tubes,"Lot number 13052B, Exp. 03/2015, NDC16781-382-15",20141016,Nationwide and Puerto Rico,NJ,"Locoid (hydrocortisone butyrate 0.1%), Cream, Net Wt. 15 gm tubes, Rx only, Manufactured for:  Onset Dermatologics, LLC, Cumberland, RI 02864 By:  Ferndale Laboratories, Inc. Ferndale, MI  48220 --- NDC 16781-382-15",20141022,Class III,Valeant Pharmaceuticals International,D-0026-2015,Letter,69359,20150403,,20141002,08807-2867,Voluntary: Firm initiated,Terminated,,,,,'NDA018514','LOCOID','HYDROCORTISONE BUTYRATE',"'Bausch Health US, LLC'",'16781-382','TOPICAL','HYDROCORTISONE BUTYRATE',"'1370770', '1370772'",'ec85def8-75bb-4a74-a983-881b14050a9b','c7b4f583-2f79-4242-8ed2-d0e19ce8a510',"'16781-382-45', '16781-382-15'",True,nan,nan,nan,'05RMF7YPWN'
United States,East Windsor,279 Princeton Hightstown Rd,Presence of Foreign Tablet: Metformin BP 1000mg was found in bottle of Metformin HCl 1000mg,,7476 bottles,"Lot#: MTSC17145-A, Exp. July 2021",20180216,Nationwide within the US,NJ,"Metformin Hydrochloride Tablets, USP 1000 mg, 500-count bottles, Rx Only,   Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit -VII (SEZ)) Mahabubnagar (Dt)_509302 India, NDC 65862-010-05.",20180228,Class III,Aurobindo Pharma Ltd.,D-0427-2018,Letter,79119,20210218,,20180202,08520-1401,Voluntary: Firm initiated,Terminated,,,,,'ANDA077095','METFORMIN HYDROCHLORIDE','METFORMIN HYDROCHLORIDE','Aurobindo Pharma Limited',"'65862-008', '65862-009', '65862-010'",'ORAL','METFORMIN HYDROCHLORIDE',"'861004', '861007', '861010'",'f6e14c96-b066-4b55-8aa2-8762b155f449','4ac6d01a-af26-44e7-ae2e-3618de0080aa',"'65862-008-50', '65862-008-60', '65862-008-90', '65862-008-01', '65862-008-33', '65862-008-05', '65862-008-99', '65862-008-45', '65862-009-50', '65862-009-60', '65862-009-90', '65862-009-01', '65862-009-33', '65862-009-05', '65862-009-99', '65862-009-44', '65862-010-50', '65862-010-60', '65862-010-90', '65862-010-01', '65862-010-33', '65862-010-05', '65862-010-99', '65862-010-46'",True,"'0365862008015', '0365862009012', '0365862010018'",nan,nan,'786Z46389E'
United States,Louisville,4441 Springdale Rd,Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.,,6456 vials,"Lot: 17REV01, Exp. 12/2019",20190510,Nationwide in the USA,KY,"Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by:  US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67",20190508,Class II,US Worldmeds LLC,D-1275-2019,Letter,82660,,,20190425,40241-1086,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078378','REVONTO','DANTROLENE SODIUM',"'US WorldMeds, LLC'",'27505-003','INTRAVENOUS','DANTROLENE SODIUM',"'856696', '1012465'",'6040962a-5507-4ca7-aa11-a98e68fab263','78801254-73a0-44ca-9222-7b3581af82d8','27505-003-67',True,nan,nan,nan,'287M0347EV'
United States,Pine Brook,10 Bloomfield Ave Bldg B Ste 2,Failed dissolution specifications,,4272 bottles,"Lot # 472990, Exp 03/2020",20190812,"Natonwide, PR",NJ,"Macrobid Urinary Tract Anitbacterial, 100 mg,  100-count bottle, Rx Only, Mfg. by: Norwich Pharmaceuticals, Inc. Norwich, NY 13815 USA Dist. by: Almatica Pharma, Inc. Pine Brook, NJ 07058 USA, NDC 52427-285-01",20190821,Class II,"Alvogen, Inc",D-1723-2019,Letter,83434,,,20190724,07058-9743,Voluntary: Firm initiated,Ongoing,['Nitrofurans [CS]'],,,,'NDA020064','MACROBID','NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE','Almatica Pharma Inc.','52427-285','ORAL',"'NITROFURANTOIN', 'NITROFURANTOIN MONOHYDRATE'","'539712', '1648755'",'0ccd1a07-3321-8416-53f4-3552e68e402d','8f270a9f-12a1-44d4-bc7e-873613555801','52427-285-01',True,nan,"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'927AH8112L', 'E1QI2CQQ1I'"
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"836,460 bags",Lot # 34-017-JT; Exp. 10/15  Lot # 35-100-JT; Exp. 11/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 NDC 0409-7902-09.",20141203,Class II,Hospira Inc.,D-0278-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA018365','POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE',"'DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE'","'Hospira, Inc.'","'0409-7901', '0409-7107', '0409-7109', '0409-7903', '0409-7904', '0409-7991', '0409-7992', '0409-7993', '0409-7998', '0409-7902', '0409-7997'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'POTASSIUM CHLORIDE'","'615099', '615100', '615107', '615111', '630796', '664704', '686185', '686534', '1863605', '1863607', '1863973', '1863975', '1863987'",'8175a5f1-5626-4f91-a0b2-024e916b8b45','d101c62c-9fd8-4bb6-e7a5-5074d189d35b',"'0409-7107-09', '0409-7109-09', '0409-7903-09', '0409-7904-09', '0409-7991-09', '0409-7992-09', '0409-7993-09', '0409-7901-03', '0409-7901-09', '0409-7998-03', '0409-7998-09', '0409-7902-03', '0409-7902-09', '0409-7997-09'",True,nan,nan,nan,"'660YQ98I10', 'LX22YL083G', '451W47IQ8X'"
United States,Warren,184 Liberty Corner Rd,Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.,,"132,336 bottles","Lot #s: 02177, 02178, Exp. 01/31/2022",20200626,Nationwide in the US,NJ,"Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.",20200708,Class II,Glaxosmithkline Consumer Healthcare Holdings,D-1361-2020,Press Release,85848,,,20200616,07059-6796,Voluntary: Firm initiated,Ongoing,,,,,'part341','CHILDRENS ROBITUSSIN HONEY COUGH AND CHEST CONGESTION DM',"'DEXTROMETHORPHAN HBR, GUAIFENESIN'",'GlaxoSmithKline Consumer Healthcare Holdings (US) LLC','0031-8760','ORAL',"'DEXTROMETHORPHAN HYDROBROMIDE', 'GUAIFENESIN'",'1790650','2d18c0fa-d53d-46a0-91b8-0b3b31fe2359','b87f700e-3414-463c-80d4-c3dbca89a488',"'0031-8760-12', '5030031876'",True,nan,nan,nan,"'9D2RTI9KYH', '495W7451VQ'"
United States,Lake Forest,1925 W Field Ct Ste 300,"Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.",,"4,206 boxes","Lot V20M54A, Exp 01/2021",20200106,Nationwide in the USA and Puerto Rico,IL,"MYORISAN (isotretinoin capsules, USP), 20mg, packaged in 30-count Capsules (3 x 10 Prescription Packs) per box, Rx only, Distributed by:  VersaPharm Inc. - An Akorn Company, Lake Forset, IL 60045; NDC 61748-302-13.",20200108,Class II,"Akorn, Inc.",D-0647-2020,Letter,84261,,,20191115,60045-4862,Voluntary: Firm initiated,Ongoing,['Retinoids [CS]'],,,,'ANDA076485','MYORISAN','ISOTRETINOIN','Versapharm Incorporated',"'61748-301', '61748-302', '61748-303', '61748-304'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1242611', '1242613', '1242615', '1663728'",'703dd363-236a-4a17-85e9-feb1b3ae540b','51ff6346-9256-4c01-9f52-417d13f2df05',"'61748-301-13', '61748-301-11', '61748-301-01', '61748-302-13', '61748-302-11', '61748-302-01', '61748-303-13', '61748-303-11', '61748-303-01', '61748-304-13', '61748-304-11', '61748-304-01'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,400 Interpace Pkwy,CGMP deviations: Product bottle may be absent of desiccant.,,,"Lot #: 1332796 A, Exp 11/2020",20200210,USA Nationwide,NJ,"Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01",20200219,Class II,Teva Pharmaceuticals USA,D-0836-2020,Letter,84797,20201103,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076772','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-725', '62037-734', '62037-726', '62037-727'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1091155', '1091170', '1091185', '1091210'",'719405ab-149f-4905-80c2-a9df737c7b94','85ef422d-af27-4126-9841-6892af1871d6',"'62037-725-01', '62037-734-01', '62037-726-01', '62037-727-01'",True,"'0362037734014', '0362037726019', '0362037725012', '0362037727016'",nan,nan,'4B3SC438HI'
United States,Parsippany,400 Interpace Pkwy,GMP Deviations: Product bottle may be absent of desiccant.,,"22,868 bottles","Lot #: 1281203M, exp. date 03/2020 and 1290113M, exp. date 04/2020",20200206,Nationwide within the United States,NJ,"Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured by: Actavis Laboratories, Inc. Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc. Parisppany, NJ 07054 USA, NDC 0591-2464-01",20200212,Class II,Teva Pharmaceuticals USA,D-0830-2020,Letter,84798,20201210,,20200127,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE',"'Actavis Pharma, Inc.'","'0591-2464', '0591-2465'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'76f9b450-b959-4911-88f3-0f8c483bcaec','43bd65ca-0b1c-42c9-bbcd-7a97d3287581',"'0591-2464-01', '0591-2465-01'",True,'0305912465016',nan,nan,'XB13HYU18U'
United States,Schaumburg,301 E Central Rd,Microbial Contamination of Non-sterile Products: contamination with Burkholderia lata.,,"a) 116,662 bottles; b) 13,296 bottles","Lot #: a) C170FY, C170FZ, C170GA, C170GB, C170GC, C177GP, C177GQ, C177GR, Exp 6/30/2022; C191KS, C191KT, C191KU, C191KW, C191KX, C191KY, C198LJ, C198LK, C198LL, C198LM, C205BH, C205BJ, C205BK, C205BL, C205BM, C205BN, Exp 7/31/2022; C219DK, C219DL, C219DM, C219DN, C219DP, C219DQ, C219DR, C219DS, Exp 8/31/2022; C240GM, C240GP, C240GQ, C240GR, Exp 9/30/2022; b) C191KR, Exp 7/31/2020",20201123,USA Nationwide,IL,"Paroex (chlorhexidine gluconate) Oral Rinse, USP 0.12%, Alcohol Free, Rx only, packaged in: a) 1 pint  (473 mL) NDC 52376-021-02; b) 4 fl oz (118 mL) NDC 52376-021-04, Sunstar Americas, Inc.",20201202,Class I,"Sunstar Americas, Inc.",D-0103-2021,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",86656,,,20201027,60195-1901,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076434','PAROEX','CHLORHEXIDINE GLUCONATE',"'Sunstar Americas, Inc.'",'52376-021','ORAL','CHLORHEXIDINE GLUCONATE',"'834127', '1437966'",'6b39ce18-d814-7f50-e053-2991aa0abc8c','4e137308-6a21-4bf9-802f-23ff78ee6797',"'52376-021-02', '52376-021-04'",True,"'0352376021043', '0352376021029'",nan,nan,'MOR84MUD8E'
United States,Belleville,681 Main St Ste 27,CGMP Deviations: Out of Specification results for either total microbial count or total organic carbon in the purified water utilized in the manufacturing process.,,533 cases,Lot #36P17 EXP 11/2019,20190813,Distributed Nationwide in the USA,NJ,"Eczema Lotion Hydrocortisone 1% / Anti-Itch Lotion, 3.5 oz (99.2 g) Distributed By: Walgreen Co. 200 Wilmot Rd. Deerfield, IL,60015. NDC 0363-0670-04, UPC 3 11917 19308 3",20190821,Class II,US Pharmaceuticals Inc.,D-1725-2019,Letter,83316,20200625,,20190711,07109-3471,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'part348','INTENSIVE HEALING ECZEMA','HYDROCORTISONE','Walgreens','0363-0670','TOPICAL','HYDROCORTISONE','103403','477234df-ba16-4e97-a96e-219034074af3','3d27f041-c554-4139-87b5-709537785f22','0363-0670-04',True,"'0311917193083', '311917193083'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','WI4X0X7BPJ'
United States,El Paso,1550 Northwestern Dr,Non-Sterility: Product is being recalled due to presence of Aspergillus Penicilloides,,"2,800,800 applicators","Lot #: 7194739, Exp. 06/25/2020; 7214841, Exp. Date 07/17/2020; 7213558, Exp. Date 07/16/2020; 7227839, Exp. Date 07/30/2020; 7276589, Exp. Date 09/20/2020; 7198824, Exp. Date 06/29/2020; 7275718, Exp. Date 09/19/2020; 7289776, Exp. Date 09/30/2020; 7306916, Exp. Date 10/12/2020; 8011665, Exp. Date 12/14/2020; 8015801, Exp. Date 12/18/2020; 8031857, Exp. Date 01/31/2021; 8033645, Exp. Date 01/31/2021; 8127657, Exp. Date 04/30/2021; 8137527, 8157141, 8158638, Exp. Date 05/31/2021; 8164530, Exp. Date 06/30/2021; 8220737, Exp. Date 07/31/2021; 8235991, Exp. Date 08/31/2021; 8043978, Exp. Date 01/31/2021; 8306694, Exp. Date 10/31/2021; 8334983, Exp. Date 11/30/2021; 9031893, 9038599, 9042938, Exp. Date 01/31/2022; 9051563, 9053560, 9072856, Exp. Date 02/28/2022; 9086532, Exp. Date 03/31/2022; 9137904, Exp. Date 05/31/2022; 9087985, Exp. Date 03/31/2022; 9191256, 9168975, Exp. Date 06/30/2022; 9218464, 9218595, Exp. Date 07/31/2022; 9228305, 9241932, 9247742, 9249471, Exp. Date 08/31/2022; 9269603, Exp. Date 09/30/2022; 9296395, 9295914, 9311076, Exp. Date 10/31/2022; 9316348, 9324565, 9345911, Exp. Date 11/30/2022; 9305775, Exp. Date 10/31/2022; 0011737, Exp. Date 12/31/2022; 0023790, 0037279, Exp. Date 01/31/2023.",20200819,"Puerto Rico, Guam, United Arab Emirates, Bahrain, Brazil, Democratic Republic of the Congo, Chile, Colombia, United Kingdom of Great Britain and Northern Ireland, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, Singapore,",TX,"ChloraPrep With Tint (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 3 mL applicators - Hi-Lite Orange  25 applicators in carton, CareFusion El Paso, TX 79912, subsidiary of Becton, Dickinson and Company, NDC 054365-400-11",20200826,Class I,"CareFusion 213, LLC",D-1510-2020,Letter,85903,,,20200623,79912-8000,Voluntary: Firm initiated,Ongoing,,,,,'NDA020832','CHLORAPREP ONE-STEP','CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL','CareFusion 213 LLC','54365-400','TOPICAL',"'CHLORHEXIDINE GLUCONATE', 'ISOPROPYL ALCOHOL'","'858726', '998282'",'b2ab2171-0717-e8de-e053-2a95a90a7c7b','cf938014-57fc-4ff2-92a0-6dee1e69c4d8','54365-400-11',True,nan,nan,nan,"'MOR84MUD8E', 'ND2M416302'"
United States,Amityville,369 Bayview Ave,Subpotent; 24 month stability test station,,lot 608917: 7764 bottles; lot 608204: 7476 bottles,"Batch 608917 (exp. 02/2014), and Batch 608204 (exp. 01/2014)",20130614,Nationwide and Puerto Rico,NY,"HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL), Rx Only, HI-TECH PHARMACAL CO., INC. AMITYVILLE, NY, NDC 50383-796-16",20130626,Class III,"Hi-Tech Pharmacal Co., Inc.",D-603-2013,Letter,65047,20160513,,20130430,11701-2801,Voluntary: Firm initiated,Terminated,,,,,'ANDA040010','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE',"'Hi-Tech Pharmacal Co., Inc.'",'50383-796','ORAL','HYDROXYZINE HYDROCHLORIDE','995241','6524cff2-ad89-4fc4-adc3-6c2476cdffa4','c848b1ae-2216-48f0-8646-165ecf7ed39b','50383-796-16',True,nan,nan,nan,'76755771U3'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.,,"6,641 bottles","Lot #: a) D17D29, L17C73, F18E73, Exp. 1/31/19; b) H17D70, K17F66, G18F26, Exp. 1/31/19; c) C18G26, F18E36, Exp. 1/31/19; d) F18A85, Exp. 1/31/19; e) K17B44, K17E29, L17D93, Exp. 1/31/19; E17B88, Exp. 5/31/19; H17A52, H17D67, Exp. 7/31/19; f) E17B01, E17E83, Exp. 5/31/19; F17C99, Exp. 6/30/19; G17C08, G17E18, H17B01, H17B66, H17F67, I17A56, Exp. 7/31/19; g) E17E27, Exp. 1/31/19, I17A33, G17D62, Exp. 7/31/19; h) E17B35, E17D90, Exp. 5/31/19, F17C13, Exp. 6/30/19, G17B25, H17C58, Exp. 7/31/19; i) G17D59, Exp. 7/31/19; j) I17A69, G17D58, Exp. 7/31/19; k) G17D56, Exp. 7/31/19.",20180824,Nationwide in the USA.,OK,"Doxycycline Hyclate USP Tablets, 100 mg packaged in a) 2-count bottles, NDC 55289-866-02; b) 6-count bottles, NDC 55289-866-06; c) 7-count bottles, NDC 55289-866-07; d) 10-count bottles, NDC 55289-866-10; e) 14-count bottles, NDC 55289-866-14; f) 20-count bottles, NDC 55289-866-20; g) 28-count bottles, NDC 55289-866-28; h) 30-count bottles, NDC 55289-866-30; i) 120-count bottles, NDC 55289-866-98; j) 300-count bottles, NDC 55289-866-87; k) 400-count bottles, NDC 55289-866-74; Rx only, Packaged By PD-Rx Pharmaceuticals, Oklahoma City, OK  73127.",20180905,Class II,"PD-Rx Pharmaceuticals, Inc.",D-1127-2018,Letter,80791,20200507,,20180807,73127-5822,Voluntary: Firm initiated,Terminated,,,,['0143-2112'],'ANDA065095','DOXYCYCLINE','DOXYCYCLINE HYCLATE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-866','ORAL','DOXYCYCLINE HYCLATE','1650143','aa57e279-69eb-5d74-e053-2995a90a3e17','c96d3986-9d92-4ec4-a319-a50aeb2f4fe7',"'55289-866-02', '55289-866-04', '55289-866-06', '55289-866-07', '55289-866-10', '55289-866-14', '55289-866-20', '55289-866-28', '55289-866-30', '55289-866-60', '55289-866-71', '55289-866-74', '55289-866-85', '55289-866-86', '55289-866-87', '55289-866-90', '55289-866-93', '55289-866-98', '55289-866-01'",nan,nan,nan,nan,'19XTS3T51U'
United States,Belleville,681 Main St Ste 27,GMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sample,,7020 units,"Lot # a) and b): 44G17, Exp. 05/2019",20190204,Nationwide within the United States,NJ,"Medline Remedy Essential Barrier Skin Protectant Ointment (petrolatum 59%) packaged in a) 2 oz tubes (NDC 53329-302-14) and b) 6 oz tubes (NDC 53329-302-41), Medline Industries Inc., Manufactured for Medline Industries Inc., Mundelien, IL 60060.",20190213,Class II,US Pharmaceuticals Inc.,D-0427-2019,Letter,81784,,,20181207,07109-3471,Voluntary: Firm initiated,Ongoing,,,,,'part347','REMEDY SKIN PROTECTANT','WHITE PETROLATUM','Medline Industries Inc.','53329-302','TOPICAL','PETROLATUM','1543744','9a2ae9dd-e409-6f9b-e053-2995a90a0868','0ec52309-642f-4667-9199-6711190fa1d4',"'53329-302-14', '53329-302-41'",True,'0888277107420',nan,nan,'4T6H12BN9U'
Canada,Toronto,150 Signet Drive,Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.,,,"Lot # 2A001, Exp. 01/15  Lot # 2A002, Exp. 01/15  Lot # 2C003, Exp. 03/15  Lot # 2F005, Exp. 06/15  Lot # 2G006, Exp. 07/15",20140903,Nationwide and Puerto Rico,,"Paroxetine HCL Controlled-Release Tablets 12.5 mg, 30-count bottle, Rx only, Manufactured by GlaxoSmithKline, RTP, NC 27709, Manufactured for Apotex Corp., Weston, FL 33328, NDC 60505-3673-3",20140910,Class II,Apotex Inc.,D-1574-2014,Letter,68967,20140923,,20140324,,Voluntary: Firm initiated,Terminated,,,,,'NDA020936','PAROXETINE HYDROCHLORIDE','PAROXETINE HYDROCHLORIDE','Apotex Corp',"'60505-1316', '60505-1317', '60505-1318', '60505-3673', '60505-3674', '60505-3675'",'ORAL','PAROXETINE HYDROCHLORIDE HEMIHYDRATE',"'1738803', '1738805', '1738807'",'ef3dcfbf-72d2-e3d3-3f1b-1f8492813892','087ff0d3-1761-47ea-a8c1-7c4cb679af97',"'60505-1316-3', '60505-1317-3', '60505-1318-3', '60505-3673-3', '60505-3674-3', '60505-3675-3'",True,"'0360505367436', '0360505367337', '0360505367535'",nan,nan,'X2ELS050D8'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"452,290 cartons","Lot #: KB50363, KB50364, KB50365, KB50366, KB50367, KB50368, KB50369, KB50370, KB50371, Exp 05/17; 01KB50598, KB50541, KB50542, KB50543, KB50544, KB50545, KB50546, KB50547, KB50548, KB50549, KB50550, KB50551, Exp 07/17; 01KB50643, 01KB50644, KB50640, KB50641, KB50642, KB50645, Exp 08/17; KB50715, KB50716, KB50717, KB50718, KB50719, KB50720, KB50757, KB50758, KB50759, KB50760, KB50761, Exp 09/17; KB50872, KB50874, KB50875, KB50876, KB50916, KB50938, KB50943, Exp 11/17; 01KB60062, 01KB60063, 01KB60064, 01KB60065, 01KB60066, 01KB60101, KB60025, KB60026, KB60027, KB60028, KB60029, KB60030, KB60031, KB60032, KB60059, KB60060, KB60061, Exp 12/17; 01KB60100, 01KB60161, Exp 01/18; 01KB60256, 01KB60257, 01KB60258, 01KB60259, 01KB60260, Exp 03/18; 01KB60292, 01KB60293, 01KB60294, 01KB60314, 01KB60321, 01KB60333, 01KB60334, 79KB60295, 79KB60296, 79KB60332, 79KB60335, 79KB60346, Exp 04/18; 01KB60393, 01KB60394, 79KB60390, 79KB60391, 79KB60392, Exp 05/18; 01KB60505, 01KB60506, 01KB60538, 79KB60502, 79KB60503, 79KB60504, 79KB60535, 79KB60536, 79KB60537, 79KB60539, 79KB60542, Exp 07/18; 01KB60589, 79KB60566, 79KB60567, 79KB60568, 79KB60569, 79KB60587, 79KB60588, Exp 08/18",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 40 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-137-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0886-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Parsippany,20 Waterview Blvd Ste 3,CGMP Deviations: Firm did not adequately investigate customer complaints.,,"A) 149,924 Bottles and B) 35,012 Bottles","A) Lot #: DM10573, Expiry: 4/30/2015; Lot #: DM11531, Expiry: 5/31/2015; Lot #: DM11532, Expiry: 5/31/2015; Lot #: DM11676, Expiry: 6/30/2015; Lot #: DM11677, Expiry: 6/30/2015; Lot #: DM12543, Expiry: 8/31/2015; Lot #: DM13333, Expiry: 11/30/2015; Lot #: DN10272, Expiry: 12/31/2015; Lot #: DN10405, Expiry: 12/31/2015; Lot #: DN10446, Expiry: 1/1/2016.  B) Lot #: DM11122, Expiry: 4/30/2015; Lot #: DM11130, Expiry: 4/30/2015; Lot #: DM11533, Expiry: 5/31/2015; Lot #: DM11674, Expiry: 6/30/2015; Lot #: DM11675, Expiry: 6/30/2015; Lot #: DM12497, Expiry: 8/31/2015; Lot #: DM13336, Expiry: 11/30/2015; Lot #: DN10289, Expiry: 12/31/2015; Lot #: DN10445, Expiry: 1/31/2016; Lot #: DN10816, Expiry: 1/31/2016; Lot #: DN10817, Expiry: 1/31/2016; Lot #: DN10976, Expiry: 2/29/2016.",20150717,U.S. Nationwide including Puerto Rico.,NJ,"Lisinopril Tablets USP, 2.5 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-927-01) and B) 500 Count Bottles (NDC: 64679-927-05), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA.",20150729,Class II,Wockhardt Usa Inc.,D-1244-2015,Letter,71104,20180509,,20150422,07054-1271,Voluntary: Firm initiated,Terminated,,,,,'ANDA078402','LISINOPRIL','LISINOPRIL','Wockhardt USA LLC.',"'64679-927', '64679-928', '64679-929', '64679-941', '64679-953', '64679-942'",'ORAL','LISINOPRIL',"'197884', '205326', '311353', '311354', '314076', '314077'",'b760b89e-02b4-8439-e053-2a95a90a9de6','e927801e-5de4-44f9-b543-789c093de655',"'64679-927-01', '64679-927-02', '64679-927-05', '64679-927-03', '64679-928-01', '64679-928-05', '64679-928-06', '64679-928-02', '64679-928-03', '64679-929-01', '64679-929-05', '64679-929-06', '64679-929-02', '64679-929-03', '64679-941-01', '64679-941-05', '64679-941-06', '64679-941-02', '64679-941-03', '64679-953-01', '64679-953-05', '64679-953-02', '64679-953-03', '64679-942-01', '64679-942-05', '64679-942-02', '64679-942-03'",True,"'0364679929063', '0364679928059', '0364679953051'",nan,nan,'E7199S1YWR'
United States,Torrance,20695 S Western Ave Ste 240,Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.,,"10,130 bottles","Lot #: XXWC, Exp. August 2018",20170523,"US: Hawaii, Guam, Saipan, SPI",CA,"Optic Splash (naphazoline hydrochloride) Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-501-01.",20170531,Class II,Sato Pharmaceutical Inc.,D-0854-2017,Letter,77161,20180313,,20170216,90501-1834,Voluntary: Firm initiated,Terminated,"['Allergens [CS]', 'Glycerol [CS]']",,"['Increased Histamine Release [PE]', 'Cell-mediated Immunity [PE]', 'Increased IgG Production [PE]']",,'part349','OPTIC SPLASH',"'NAPHAZOLINE HYDROCHLORIDE, GLYCERIN'","'Sato Pharmaceutical, Co., Ltd.'",'49873-501','OPHTHALMIC',"'NAPHAZOLINE HYDROCHLORIDE', 'GLYCERIN'",'1243999','b7c12f8f-0494-7d53-e053-2a95a90ae02e','e3d60c20-7cbc-4728-8e42-441b64608b88','49873-501-01',True,'0349873502014',"'N0000185370', 'N0000175629', 'N0000184306', 'N0000185001', 'M0000728', 'M0009417'",'Non-Standardized Chemical Allergen EPC',"'MZ1131787D', 'PDC6A3C0OX'"
United States,Hazelwood,675 James S McDonnell Blvd,Labeling: incorrect or missing lot number and/or expiration date,,6600 bottles,"Lot #: B201B, Exp April 2015; B346D, Exp August 2015.",20150610,Costa Rica,MO,"MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP); 37% Organically Bound Iodine For Gastrointestinal Radiography; Oral or rectal use only; Rx only; 30 mL; Single-Unit Container; ; Mallinckrodt Inc., St. Louis, MO 63042. NDC 0019-4816-04",20150617,Class II,"Mallinckrodt, Inc.",D-1132-2015,Letter,71220,20170710,,20150515,63042-2301,Voluntary: Firm initiated,Terminated,,,,,'ANDA087388','MD GASTROVIEW','DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM','Liebel-Flarsheim Company LLC','0019-4816',"'ORAL', 'RECTAL'","'DIATRIZOATE MEGLUMINE', 'DIATRIZOATE SODIUM'",nan,'79425e73-456a-458a-986d-baf4291584a2','b348b1cf-6250-4ab6-b2bf-3bff86628c53','0019-4816-04',True,'0300194816044',nan,nan,"'3X9MR4N98U', 'V5403H8VG7'"
United States,Eatontown,401 Industrial Way West,Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).,,"1,896 shelf packs","Lot #: 106352, Exp 10/18",20171122,Nationwide in the USA and Puerto Rico,NJ,"Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.",20171129,Class III,West-Ward Pharmaceuticals Corp.,D-0094-2018,Letter,78415,20200401,,20171106,07724-2209,Voluntary: Firm initiated,Terminated,,,,,'ANDA087702','DEXAMETHASONE SODIUM PHOSPHATE','DEXAMETHASONE SODIUM PHOSPHATE','Hikma Pharmaceuticals USA Inc.',"'0641-0367', '0641-6145', '0641-6146'","'INTRAMUSCULAR', 'INTRAVENOUS'",'DEXAMETHASONE SODIUM PHOSPHATE',"'309696', '1116927'",'9fd6a1b2-125c-4c74-a686-06c3c5fca7ab','0277cc0a-2fd4-4605-a310-b613be84ee26',"'0641-6145-01', '0641-6145-25', '0641-6146-01', '0641-6146-25', '0641-0367-21', '0641-0367-25'",True,nan,nan,nan,'AI9376Y64P'
United States,Miami,11960 SW 144th St,"Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.",,149631 boxes of 8 patches and 15809 boxes of 2 patches,a) 82292 Exp. 02/2019;    b) 82139 Exp. 10/2018; 82292 Exp. 02/2019; and 82598 Exp. 04/2019,20180925,Nationwide,FL,"Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6650-8",20181003,Class II,"Noven Pharmaceuticals, Inc.",D-1208-2018,Letter,80997,20200909,,20180907,33186-6109,Voluntary: Firm initiated,Terminated,['Estradiol Congeners [CS]'],['Estrogen Receptor Agonists [MoA]'],,,'NDA203752','MINIVELLE','ESTRADIOL',"'Noven Therapeutics, LLC'","'68968-6610', '68968-6625', '68968-6637', '68968-6650', '68968-6675'",'TRANSDERMAL','ESTRADIOL',"'241946', '242891', '242892', '248478', '1149632', '1356979', '1356997', '1357007', '1357009', '1551622'",'caa6e475-2f1c-4b4a-99c1-9895b4261885','6c5c47ab-28ee-11e1-bfc2-0800200c9a66',"'68968-6625-1', '68968-6625-8', '68968-6637-1', '68968-6637-8', '68968-6650-1', '68968-6650-8', '68968-6675-1', '68968-6675-8', '68968-6610-1', '68968-6610-8'",True,"'0368968665014', '0368968663713', '0368968667513', '0368968661016'","'M0447348', 'N0000175825', 'N0000000100'",'Estrogen EPC','4TI98Z838E'
United States,Huntsville,120 Vintage Dr NE,Subpotent; 6 month stability time point,,"159,913 tablets","100 count: T147F13A, Exp. 05/2015; 21 count: S003M14, Exp. 05/2015",20140922,Nationwide,AL,"MethylPREDNISolone TABLETS, USP 4 mg, a) 100 count bottles (NDC 0603-4593-21)  and b) 21 count blister pack (NDC 0603-4593-15), Rx only, Mfg for:  QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL  35811",20141001,Class III,Qualitest Pharmaceuticals,D-1605-2014,Letter,69233,20160127,,20140911,35811-8216,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040183','METHYLPREDNISOLONE','METHYLPREDNISOLONE','Par Pharmaceutical','0603-4593','ORAL','METHYLPREDNISOLONE',"'259966', '762675'",'9cc942c1-f5d4-4b61-b57d-a4189188c217','c84cf5e6-746d-41fb-b3d8-2c0b8ba989af',"'0603-4593-15', '0603-4593-21'",True,'0306034593212',"'N0000175576', 'N0000175450'",'Corticosteroid EPC','X4W7ZR7023'
United States,Princeton,506 Carnegie Ctr Ste 400,Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins,,"17,500 units","Lot #: JX907, Exp. Date 02/2021",20200501,Nationwide within the United States,NJ,"Infuvite PEDiatric Pharmacy,  kit in 1 carton (40 mL fill in a 50 mL) vial  1 and (10 mL) in vial 2, Rx Only,  Distributed by: Baxter Healthcare Corporation Clintec Nutrition Division Deerfield, IL 60015 USA, NDC 54643-5647-0",20200513,Class II,"Sandoz, Inc",D-1259-2020,Letter,85538,,,20200421,08540-6243,Voluntary: Firm initiated,Ongoing,,,,,'NDA021646','PEDIATRIC INFUVITE MULTIPLE VITAMINS',"'ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN'",'Sandoz Manufacturing Inc','54643-5647',nan,nan,"'1305217', '1305222'",'c00b00ac-89c0-4f47-a518-60911f38f462','6d06546e-8b0a-4490-82d9-397bd902a044','54643-5647-0',True,nan,nan,nan,nan
India,Pithampur,"Unit 1, Plot 2, SEZ, Phase II,","Contraceptive Tablets Out of Sequence- First 4 pills of the packet are brown, instead of the last four pills and the expiry/lot was not printed on the package.","Misc Zone Apparel Park, Dist. Dhar","24,652 tablets",Batch Number L600518; Exp. 05/18,20170815,Nationwide,,"Mibelas 24 Fe (Norethindrone acetate and Ethinyl estradiol 1 mg/0.02 mg chewable and ferrous Fumarate 75 mg) Tablets, wallet of 28 tablets (NDC 68180-911-11), Carton of 3 wallets (NDC 68180-911-13), Rx Only, Manufactured by: Lupin Limited, India, Distributed by Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202",20170823,Class I,Lupin Limited (Unit 1),D-1093-2017,Letter,77323,20190530,,20170516,,Voluntary: Firm initiated,Terminated,,,,,'ANDA206287','MIBELAS 24 FE',"'NORETHINDRONE ACETATE, ETHINYL ESTRADIOL AND FERROUS FUMARATE'","'Lupin Pharmaceuticals, Inc.'",'68180-911',nan,nan,"'259176', '1426288', '1426600', '1873704'",'f710ee5e-437d-4e81-b73a-af0a34ecc267','3f82d240-1d26-409e-87cd-10c1d5a511c2',"'68180-911-11', '68180-911-13'",True,nan,nan,nan,nan
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"85,680 vials","Lot #: 34-440-DD, Exp 10/15",20140605,Nationwide.,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.25%, Preservative-Free, 10 mL (25 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL  60045 USP, NDC 0409-1559-10.",20140611,Class I,Hospira Inc.,D-1358-2014,Press Release,68048,20170316,,20140421,60045-2579,Voluntary: Firm initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
China,Wuhan,Building,"CGMP Deviations: due to the loss of product manufacturing records and retain product samples, there is no assurance that the product will remain within specification through the labeled expiration date.","F, No.5, Kangda Street","1,800 pouches","Batch #: 170731, Exp 2020.07; 180504; Exp 2021.05",20200528,Nationwide in the USA,,"Mencaine (lidocaine 4.5%, menthol 5%) Patch, 1 patch per pouch, Manufactured For: Terrain Pharmaceuticals, Reno, NV 89501; NDC 53225-1090-1.",20200603,Class II,"Wuhan Bingbing Pharmaceutical Co., Ltd.",D-1279-2020,E-Mail,85726,,,20200519,,Voluntary: Firm initiated,Ongoing,['Amides [CS]'],,['Local Anesthesia [PE]'],,'part348','MENCAINE',"'LIDOCAINE, MENTHOL'",'Terrain Pharmaceuticals','53225-1090','TOPICAL',"'LIDOCAINE', 'MENTHOL'",'1653326','b5e802ed-9ee6-de15-e053-2a95a90adb13','57583a1d-1369-609f-e053-2991aa0a292c','53225-1090-1',True,nan,"'N0000175682', 'M0000897', 'N0000175426', 'N0000175976'","'Amide Local Anesthetic EPC', 'Antiarrhythmic EPC'","'98PI200987', 'L7T10EIP3A'"
United States,Eatontown,465 Industrial Way W,"Labeling: Not elsewhere classified: On 12/12/11, DEA published a final rule in the Federal Register making this product a schedule IV (C-IV)controlled substance.  This product is being recalled because this controlled product was not relabeled with the required ""C-IV"" imprint on the label for products distributed after the 06/11/12 deadline.",,1763 bottles,Lot #: 69160A,20130315,Nationwide,NJ,"Carisoprodol Tablets, USP, 350 mg Rx Only, 100 tablets per bottle, Rx Only, Manufactured by: West-ward Pharmaceutical Corp., Eatontown, NJ 07724, NDC 0143-1176-01.",20130327,Class III,West-ward Pharmaceutical Corp.,D-201-2013,Letter,64104,20141218,,20121130,07724-2209,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA040124','CARISOPRODOL','CARISOPRODOL','Hikma Pharmaceuticals USA Inc.','0143-1176','ORAL','CARISOPRODOL','197446','be6b69eb-b922-4345-af4f-18d46d80735b','88cd0b26-6575-4132-9749-0f038d8663c7',"'0143-1176-01', '0143-1176-05', '0143-1176-10'",True,'0301431176013',"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','21925K482H'
United States,Lake Forest,1925 W Field Ct Ste 300,Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide,,"8,574 bottles","Lot# 6K89A, 6K90A, 6K92A, exp 9/18",20180829,Nationwide USA,IL,"Azelastine HCl Ophthalmic Solution 0.05%, 6 mL in 10 mL HDPE bottle, 1 bottle per box, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-718-10",20180905,Class III,"Akorn, Inc.",D-1168-2018,Letter,80767,20201103,,20180808,60045-4862,Voluntary: Firm initiated,Terminated,,,,,'ANDA203660','AZELASTINE HYDROCHLORIDE','AZELASTINE HYDROCHLORIDE',"'Akorn, Inc.'",'17478-718','OPHTHALMIC','AZELASTINE HYDROCHLORIDE','860805','ccd9934b-da19-4b05-9ebd-5b4cf54fdf6c','a31f80f5-2a31-4c4c-85a4-5e597c6e2f8e','17478-718-10',True,'0317478718109',nan,nan,'0L591QR10I'
United States,Baudette,455 Idc Rd Sw,Labeling: Incorrect expiration date.  Product dated with 24-month expiration date instead of 18-months.,,6780 bottles,Lot: 19T16 Exp. Jan. 2022,20201021,Distributed Nationwide in the USA,MN,"Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product) Extended-Release Capsules, 25 mg, 100-count bottle, Rx Only, Mfd. for: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 NDC 43975-281-10",20201028,Class III,"ANI Pharmaceuticals, Inc.",D-0047-2021,Letter,86584,,,20201009,56623-2467,Voluntary: Firm initiated,Ongoing,,,,,'ANDA205401',"'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE'","'ANI Pharmaceuticals, Inc.'","'43975-277', '43975-278', '43975-279', '43975-280', '43975-282', '43975-281'",'ORAL',"'AMPHETAMINE SULFATE', 'AMPHETAMINE ASPARTATE MONOHYDRATE', 'DEXTROAMPHETAMINE SULFATE', 'DEXTROAMPHETAMINE SACCHARATE'","'861221', '861223', '861225', '861227', '861232', '861237'",'3e6c4823-1ddf-40f0-91b0-f7a6c010df38','6438480f-1147-42b6-826d-4e1e1f8ff007',"'43975-277-10', '43975-278-10', '43975-279-10', '43975-280-10', '43975-282-10', '43975-281-10'",True,"'0343975278105', '0343975280108', '0343975282102'",nan,nan,"'JJ768O327N', 'O1ZPV620O4', '6DPV8NK46S', 'G83415V073'"
United States,Princeton,107 College Rd E,Failed Tablet/Capsule Specifications:  Product recalled due to reports of breakage and leakage of Paricalcitol capsules.,,4383 bottles,"Lot #s: C404653, C404654, C404655, Exp 05/2016; C505010, Exp 06/2017",20160218,Nationwide,NJ,"Paricalcitol Capsules, 2 mcg, 30 capsules per bottle, Rx Only, Mfd by: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-664-30",20160224,Class III,"Dr. Reddy's Laboratories, Inc.",D-0720-2016,Letter,72648,20170622,,20151104,08540-6623,Voluntary: Firm initiated,Terminated,['Cholecalciferol [CS]'],,,,'ANDA091412','PARICALCITOL','PARICALCITOL',"""Dr. Reddy's Laboratories Limited""","'55111-663', '55111-664', '55111-665'",'ORAL','PARICALCITOL',"'577315', '577317', '577324'",'9cdba353-c828-7ee6-0fed-9eb342df7ffc','aa1a80e9-8778-a03e-5d53-d4b6a6363169',"'55111-663-30', '55111-663-01', '55111-663-05', '55111-663-79', '55111-663-81', '55111-664-30', '55111-664-01', '55111-664-05', '55111-664-79', '55111-664-81', '55111-665-30', '55111-665-01', '55111-665-05', '55111-665-79', '55111-665-81'",True,nan,"'M0004229', 'N0000175908'",'Vitamin D3 Analog EPC','6702D36OG5'
United States,Deerfield,1 Baxter Pkwy,"Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag",,"105,216 containers","Lot #: P285288, Exp 11/13",20140314,"Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.",IL,"5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015 USA, Product code 2B0089, NDC 0338-0017-38.",20140326,Class I,Baxter Healthcare Corp.,D-1162-2014,Letter,67092,20160921,,20131121,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA016673','DEXTROSE','DEXTROSE MONOHYDRATE','Baxter Healthcare Corporation',"'0338-0017', '0338-0023'",'INTRAVENOUS','DEXTROSE MONOHYDRATE',"'1795477', '1795480', '1795481', '1795607', '1795609', '1795610', '1795612', '1795616', '1795618', '1795621'",'7fe5f9a3-7a84-41ff-b71e-00285ff215a9','3bb406a9-f5cb-403a-b1bb-5c4facbea3d5',"'0338-0017-10', '0338-0017-41', '0338-0017-11', '0338-0017-31', '0338-0017-48', '0338-0017-18', '0338-0017-38', '0338-0017-01', '0338-0017-02', '0338-0017-03', '0338-0017-04', '0338-0023-02', '0338-0023-03', '0338-0023-04'",True,nan,nan,nan,'LX22YL083G'
United States,Central Islip,550 S Research Pl,Presence of Particulate Matter.,,75968 vials,"Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.",20190415,Nationwide in the U.S.A.,NY,"Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.",20190424,Class II,"InvaGen Pharmaceuticals, Inc.",D-1125-2019,Letter,82463,,,20190322,11722-4415,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210362','TESTOSTERONE CYPIONATE','TESTOSTERONE CYPIONATE','Cipla USA Inc.',"'69097-536', '69097-537'",'INTRAMUSCULAR','TESTOSTERONE CYPIONATE',"'835829', '835840', '2047882'",'1ae5e046-507e-4f25-a717-386480350436','78d55bad-4a5b-4e21-aeb8-a4c6346208be',"'69097-536-37', '69097-537-37', '69097-537-31'",True,"'0369097537319', '0369097536374', '0369097537371'",nan,nan,'M0XW1UBI14'
United States,Elizabeth,200 Elmora Ave,Subpotent Drug: During routine stability testing one tablet was found with tablet weight below specification.,,"13,608 bottles",lot 58468552 Exp. 05/15,20140221,Nationwide,NJ,"Clonazepam Tablets, USP 2 mg 100 tablets Manufactured by: Actavis Elizabeth LLC 200 Elmora Avenue, Elizabeth, NJ 0737 USA  NDC 0228-3005-11    packaged in White/Round HDPE 75 CC with white/round plastic 33 mm CRC closure shipped in corrugated 75 cc carton (24 bottles/carton)",20140305,Class II,Actavis Elizabeth LLC,D-1087-2014,Letter,67053,20140602,,20131106,07202-1106,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA074869','CLONAZEPAM','CLONAZEPAM',"'Actavis Pharma, Inc.'","'0228-3003', '0228-3004', '0228-3005'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529'",'9b580604-0d7c-44b2-b563-4750a2a263d2','a58fe03c-2b5c-40dc-b592-3e376b2dc9f0',"'0228-3003-11', '0228-3003-50', '0228-3004-11', '0228-3004-50', '0228-3005-11', '0228-3005-50'",True,"'0302283005117', '0302283003113', '0302283004110'","'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,East Brunswick,2 Tower Center Blvd Ste 1102,Failed Stability Specifications: Out of Specification results obtained for preservative Methylparaben content.,,"127,517 bottles","Lot #: 7225075, 7225076, 7225077, 7225078, 7225079, 7225080 Exp 7/2017; 7225180, 7225181, 7225322, 7225323, Exp 8/2017; 7225649A, 7225650A , 7225651A , 7225652A, 7225653A, 7225654A, Exp 9/2017",20170523,U.S.A. Nationwide,NJ,"Benzonatate capsules, 200 mg, 100-count bottle, Rx only, Manufactured by: Strides Shasun Limited Bangaluru -560076 India, Distributed by Strides Pharma Inc East Brunswick, NJ 08816, NDC 64380-713-06",20170531,Class III,Strides Pharma INC,D-0858-2017,Letter,77311,20171222,,20170509,08816-1100,Voluntary: Firm initiated,Terminated,,,['Decreased Tracheobronchial Stretch Receptor Activity [PE]'],,'ANDA091133','BENZONATATE','BENZONATATE','Strides Pharma Science Limited',"'64380-712', '64380-713'",'ORAL','BENZONATATE',"'197397', '283417'",'f9d8d3dd-fde8-4939-9a6e-cf5372c3c430','89f5d18e-5ef4-42a3-bc6f-abf4f308462b',"'64380-712-06', '64380-712-07', '64380-713-06', '64380-713-07'",True,"'0364380712077', '0364380712060', '0364380713074'","'N0000009010', 'N0000175796'",'Non-narcotic Antitussive EPC','5P4DHS6ENR'
United States,Waco,8301 Mars Dr,Failed Impurities/Degradation Specifications.,,"715,041 bottles","Lot #: a) 94659 Exp. FEB-2019; b) 94715, Exp. JAN-2019; 94757, Exp. FEB-2019, 94715A, Exp. JAN-2019; 95297, Exp. MAR-2019;  c) 95223 Exp. MAR-2019; d) 95220 Exp. MAR-2019",20171113,"Nationwide and  Barbados, Curacao, Dominican Republic, Guyana, Jamaica, and Trinidad and Tobago.",TX,"Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..",20171122,Class III,"Allergan Sales, LLC",D-0077-2018,Letter,78325,20191030,,20171019,76712-6578,Voluntary: Firm initiated,Terminated,,,,,'NDA021398','COMBIGAN',"'BRIMONIDINE TARTRATE, TIMOLOL MALEATE'","'Allergan, Inc.'",'0023-9211','OPHTHALMIC',"'BRIMONIDINE TARTRATE', 'TIMOLOL MALEATE'","'861635', '861637'",'95283c91-1b7f-4a85-b6db-7e5b197bb2c5','feaf1480-a4b8-4486-992a-96be3a596243',"'0023-9211-03', '0023-9211-05', '0023-9211-10', '0023-9211-15'",True,'0300239211056',nan,nan,"'4S9CL2DY2H', 'P8Y54F701R'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,15541 bottles,Lot CLO17006A exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets USP 25 mg 90 film coated tablets Rx Only    Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)    NDC 23155-644-09",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1291-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,Bannockburn,2801 Lakeside Dr Ste 209,Stability Data Does Not Support Expiry: Printed expiration date should be Nov 2013 rather than Nov 2014.,,261 vials,Lot Number: 0M396; Expiry: Nov 2014,20140312,US: Nationwide and Taiwan,IL,"Photofrin (porfimer sodium) for Injection, 75 mg Single Use Flip-Top Vial, Rx Only. Manufactured for: Pinnacle Biologics, Inc. Bannockburn, IL 60015. NDC:76128-155-75",20140319,Class III,Pinnacle Biologics Inc,D-1157-2014,Letter,67688,20150522,,20140210,60015-1271,Voluntary: Firm initiated,Terminated,,,,,'NDA020451','PHOTOFRIN','PORFIMER SODIUM',"'Pinnacle Biologics, Inc.'",'76128-155','INTRAVENOUS','PORFIMER SODIUM',"'242166', '687066'",'d4fb7cd9-a14d-4f79-9a37-0ed532b84b36','5c4841b4-fbc0-4163-8ee1-cb28629cbfbf','76128-155-75',True,nan,nan,nan,'Y3834SIK5F'
United States,Lake Forest,275 N Field Dr,Lack of Assurance of Sterility: Potential of punctures through the overwrap and primary container which may result in IV bag leaks.,,"823,296 bags",Lot # 33-095-JT; Exp. 09/15  Lot # 36-030-JT; Exp. 12/15,20141125,"Nationwide, Puerto Rico, and U.S. Virgin Islands.",IL,"5% Dextrose and 0.45% Sodium Chloride Injection, USP, 1000 mL container, Rx Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7926-09.",20141203,Class II,Hospira Inc.,D-0280-2015,Letter,69494,20151228,,20141014,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA017606','DEXTROSE AND SODIUM CHLORIDE','DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE',"'Hospira, Inc.'","'0409-7924', '0409-7925', '0409-7926', '0409-7941'",'INTRAVENOUS',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE'","'1794902', '1794904', '1794905', '1795147', '1795149', '1795150', '1795250', '1795252', '1795254', '1795344', '1795346', '1795348'",'62889680-51df-4213-9667-4f3433523499','4c777705-87f8-4eef-e190-22105e5a61fd',"'0409-7924-02', '0409-7924-03', '0409-7924-09', '0409-7925-02', '0409-7925-03', '0409-7925-09', '0409-7926-02', '0409-7926-03', '0409-7926-09', '0409-7941-02', '0409-7941-03', '0409-7941-09'",True,nan,nan,nan,"'LX22YL083G', '451W47IQ8X'"
United States,Elizabeth,200 Elmora Ave,Failed Capsule/Tablet Specifications: Actavis has received several complaint for clumping and breaking of capsules with some bottles showing popped out bottle bottom (round bottom) and creased labels from one distribution center.,,"24,240 Bottles","Lot #s: G01960A1, Exp 09/2015, G01967A1, Exp 10/2015",20150108,Puerto Rico,NJ,"Gabapentin Capsules, USP, 300 mg, Rx Only, 100 capsules per bottle, Manufactured by: Actavis Pharma Manufacturing Pvt. Ltd., Plot No 101, 102, 107, & 108, SIDCO Pharmaceutical Complex, Alathurt, Kanchipuram Dist-603 110, Tamlinadu, India, Distributed by: Actavis Elizabeth LLC, 700 Elmora Ave, Elizabeth, NJ 07207 USA, NDC 45963-556-11",20150114,Class II,Actavis Elizabeth LLC,D-0337-2015,Letter,70001,20151120,,20141215,07202-1106,Voluntary: Firm initiated,Terminated,,,,,nan,'GABA 300-EZS','GABAPENTIN','PureTek Corporation','59088-725',nan,nan,'310431','b43e4780-f902-89d9-e053-2a95a90a6792','bb29692e-1546-4d05-a46a-93baf4172c7d',"'59088-725-00', '45963-556-11'",True,'0731477272217',nan,nan,nan
United States,Cherry Hill,2 Esterbrook Ln,Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.,,"97,890 vials","Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021",20200821,Nationwide in the U.S.,NJ,"Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.",20200902,Class II,Hikma Pharmaceuticals USA Inc.,D-1533-2020,Letter,86243,,,20200814,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA076931','BUPRENORPHINE HYDROCHLORIDE','BUPRENORPHINE HYDROCHLORIDE','Hikma Pharmaceuticals USA Inc.','0143-9246',"'INTRAMUSCULAR', 'INTRAVENOUS'",'BUPRENORPHINE HYDROCHLORIDE','238129','6436c8a2-d48b-461e-947b-b4dfed184aae','adc1167e-910e-4d7b-abdc-751d3df0c3dc',"'0143-9246-01', '0143-9246-05'",True,nan,nan,nan,'56W8MW3EN1'
United States,Plainsboro,666 Plainsboro Rd Bldg 200 Ste 230,CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.,,"4277 bottles (4,277,000 tablets)",BLI710A Nov 2019,20190709,Nationwide,NJ,"Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only  Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536   Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA   NDC 33342-045-44",20190717,Class II,Macleods Pharma Usa Inc,D-1458-2019,Letter,83151,,,20190620,08536-0009,Voluntary: Firm initiated,Ongoing,,,,,'ANDA202230','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Macleods Pharmaceuticals Limited',"'33342-044', '33342-045', '33342-046'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'e852e09d-15b7-4cd6-b0f0-16a0a91d8e89','85d69d02-c5ef-467e-94aa-903100218795',"'33342-044-10', '33342-044-12', '33342-044-07', '33342-044-44', '33342-045-10', '33342-045-12', '33342-045-07', '33342-045-44', '33342-046-10', '33342-046-12', '33342-046-07', '33342-046-44'",True,"'0333342046109', '0333342044105', '0333342045072', '0333342045102'",nan,nan,'3ST302B24A'
United States,Pulaski,615 N 1st St,Failed Stability Specifications.,,5953 bottles,"Lot #s: 067180011A; 067180012A, Exp. 04/2021; 06718027B1 Exp. 09/2021",20190917,Nationwide in the U.S.,TN,"AVKARE Fexofenadine Hydrochloride Tablets USP Antihistamine 180 mg, 500 Tablets per bottle, NDC 42291-297-50.",20190918,Class II,AVKARE Inc.,D-1875-2019,Letter,83700,,,20190828,38478-2403,Voluntary: Firm initiated,Ongoing,,,,"['13107-066', '13107-067']",'ANDA202039','FEXOFENADINE HYDROCHLORIDE','FEXOFENADINE HYDROCHLORIDE','AvKARE',"'42291-297', '42291-296'",'ORAL','FEXOFENADINE HYDROCHLORIDE',"'997420', '997501'",'a8214928-6b62-9001-e053-2a95a90ab076','6e920dce-66b7-f330-c527-4aedec664915',"'42291-296-90', '42291-297-90', '42291-297-50'",nan,nan,nan,nan,'2S068B75ZU'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping,,,Lot #211836 Exp - 11/30/2016,20140731,Nationwide,NJ,"Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlorothiazide), 40 mg/5 mg*/25 mg 30 count bottles, Rx Only  Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-116-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1504-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA200175','TRIBENZOR','OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-114', '65597-115', '65597-116', '65597-117', '65597-118'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'AMLODIPINE BESYLATE', 'HYDROCHLOROTHIAZIDE'","'999967', '999971', '999986', '999990', '999991', '999995', '999996', '1000000', '1000001', '1000005'",'987ccd89-d9d0-4eb4-9afb-e28bb9389d3c','5562b3f5-8757-11de-8a39-0800200c9a66',"'65597-114-10', '65597-114-07', '65597-114-30', '65597-114-70', '65597-114-90', '65597-115-10', '65597-115-07', '65597-115-30', '65597-115-70', '65597-115-90', '65597-116-10', '65597-116-07', '65597-116-30', '65597-116-70', '65597-116-90', '65597-117-10', '65597-117-07', '65597-117-30', '65597-117-70', '65597-117-90', '65597-118-10', '65597-118-07', '65597-118-30', '65597-118-70', '65597-118-90'",True,"'0365597115309', '0365597117303', '0365597114302', '0365597116306', '0365597118904'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'864V2Q084H', '0J48LPH2TH', '6M97XTV3HD'"
United States,Deerfield,1 Baxter Pkwy,Presence of Particulate Matter: particulate matter identified as fibers and/or plastics,,"171,672 bags","Lot #: P309476, Exp 10/14",20140918,"Nationwide, Puerto Rico, Singapore, and Hong Kong",IL,"Potassium Chloride Injection, 20 mEq per 50 mL, 50 mL Sterile Single Dose Container bag, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, NDC 0338-0703-41, Product Code 2B0822.",20140924,Class I,Baxter Healthcare Corp.,D-1593-2014,Letter,68728,20160921,,20140711,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA019904','POTASSIUM CHLORIDE','POTASSIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0703', '0338-0705', '0338-0709'",'INTRAVENOUS','POTASSIUM CHLORIDE',"'312507', '1860239', '1860241', '1860463', '1860466'",'4680b223-6eb1-4108-9ca8-e3a523716040','092ddee4-572d-4771-8d95-880cea01097e',"'0338-0703-41', '0338-0703-48', '0338-0705-41', '0338-0705-48', '0338-0709-48'",True,nan,nan,nan,'660YQ98I10'
United States,Parsippany,400 Interpace Pkwy,Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).,,"3,040 bottles","Lot #: 512146A, Exp 01/31/2014",20130204,Nationwide and Puerto Rico,NJ,"Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.",20130213,Class II,Watson Pharmaceuticals,D-145-2013,E-Mail,64056,20140730,,20121218,07054-1120,Voluntary: Firm initiated,Terminated,,,,,'ANDA075401','TAZTIA','DILTIAZEM HYDROCHLORIDE',"'Actavis Pharma, Inc.'","'62037-696', '62037-697', '62037-698', '62037-699', '62037-700'",'ORAL','DILTIAZEM HYDROCHLORIDE',"'830795', '830801', '830837', '830845', '830861', '831196', '831248', '831300', '831325', '831349'",'2a5cd549-8cd1-42f1-a2eb-637d5a967665','c9f74c57-3fe9-470b-9096-31d0acb22f7e',"'62037-696-30', '62037-696-90', '62037-697-30', '62037-697-90', '62037-698-30', '62037-698-90', '62037-699-30', '62037-699-90', '62037-700-30', '62037-700-90'",True,nan,nan,nan,'OLH94387TE'
United States,Deerfield,1 Baxter Pkwy,CGMP Deviations,,33600 bags,"Lot #: P380287, Exp. date 12/2019",20180827,TX and MS only,IL,"0.9% Sodium Chloride Injection USP 100 mL bags, Rx only, Baxter Healthcare Corporation Deerfield, IL 60015 USA, NDC 0338-0049-18",20180905,Class II,Baxter Healthcare Corporation,D-1128-2018,Letter,80881,20191030,,20180821,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA018016','SODIUM CHLORIDE','SODIUM CHLORIDE','Baxter Healthcare Corporation',"'0338-0043', '0338-0049'",'INTRAVENOUS','SODIUM CHLORIDE',"'1807551', '1807552', '1807627', '1807630', '1807631', '1807632', '1807633', '1807634', '1807639'",'7c3ca9ca-a805-47ce-8aea-4f7ba2a9ed0e','f55bd888-5e01-474d-871b-24654c070178',"'0338-0049-01', '0338-0049-02', '0338-0049-03', '0338-0049-04', '0338-0049-10', '0338-0049-41', '0338-0049-11', '0338-0049-31', '0338-0049-48', '0338-0049-18', '0338-0049-38', '0338-0043-03', '0338-0043-04'",True,nan,nan,nan,'451W47IQ8X'
United States,Miami,11960 Sw 144th St,"Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained.",,"335,910 patches","Lot #59824, Exp 04/13",20130502,Nationwide and Puerto Rico.,FL,"Daytrana (methylphenidate) transdermal system patch, Delivers 10 mg over 9 hours (1.1 mg/hr), 1 patch per pouch, packaged in 30-count patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186; NDC 68968-5552-3.",20130508,Class II,"Noven Pharmaceuticals, Inc.",D-312-2013,Letter,64710,20161228,,20130131,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,1925 W Field Ct Ste 300,CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.,,"4,885 bottles",Batch# 359774; Exp. 09/02/19,20180108,Nationwide,IL,"Gabapentin Oral Solution, 250 mg/5 mL (50 mg/mL) in a 470 mL amber-colored bottle, Rx Only.  Manufactured by: Hi-Tech Pharmacal Co., Inc.  Amityville, NY 11701.  NDC:  50383-311-47",20180117,Class III,Akorn Inc,D-0211-2018,Letter,78730,20190410,,20171215,60045-4862,Voluntary: Firm initiated,Terminated,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA078974','GABAPENTIN','GABAPENTIN',"'Hi-Tech Pharmacal Co., Inc.'",'50383-311','ORAL','GABAPENTIN','283523','8d0fc680-0336-46a6-ab6b-bf882b4a6155','c64c09c9-0567-4a4f-b2c6-8f667986c9af',"'50383-311-47', '50383-311-05', '50383-311-07', '50383-311-06', '50383-311-09'",True,nan,"'N0000175753', 'N0000008486'",'Anti-epileptic Agent EPC','6CW7F3G59X'
United States,New York,235 East 42nd Street,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,,"31,569 HDPE Bottles","Lot # a) H79652, Exp. 10/15; b) H79653, Exp. 10/15",20141209,"Pfizer shipped the affected product to 4,447 direct accounts.     No federal government accounts received the affected product directly from Pfizer Inc.",NY,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.",20141217,Class II,Pfizer Inc.,D-0292-2015,Letter,69724,20160927,,20141203,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA020931','TIKOSYN','DOFETILIDE','Pfizer Laboratories Div Pfizer Inc',"'0069-5800', '0069-5810', '0069-5820'",'ORAL','DOFETILIDE',"'284404', '284405', '285016', '310003', '310004', '310005'",'eff77cc8-396a-4421-9f9d-2c5aa66daa18','02438044-d6a3-49e9-a1ac-3aad21ef2c8c',"'0069-5800-61', '0069-5800-60', '0069-5800-43', '0069-5810-61', '0069-5810-60', '0069-5810-43', '0069-5820-61', '0069-5820-60', '0069-5820-43'",True,"'0300695800603', '0300695810602', '0300695820601'",'N0000175426','Antiarrhythmic EPC','R4Z9X1N2ND'
United States,Miami,11960 Sw 144th St,Defective Delivery System: Out of specification for mechanical peel.,,"786,900 patches","Lots #: 87580, Exp 4/2021, 87819, Exp 4/2021, 88244, Exp 6/2021, 88245, Exp 6/2021, 88532, Exp 06/2021 & 88533, Exp 7/2021.",20210303,Nationwide in the USA,FL,"Daytrana (methylphenidate transdermal system) Delivers 20 mg over 9 hours (2.2 mg/hr) Contains: 30 Patches in a foil-sealed polypropylene tray, packed in a paper carton, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL, 33186, By Noven Pharmaceuticals, Inc., Miami, FL, 33186, NDC 68968-5554-3.",20210310,Class II,Noven Pharmaceuticals Inc,D-0295-2021,Letter,87373,,,20210219,33186-6109,Voluntary: Firm initiated,Ongoing,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter:  particulate matter identified as an insect in one vial.,,"72,000 units","Lot # 56-148-EV, Exp 8/1/2017",20160523,Nationwide,IL,"8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL), 50 mL, Rx only, Hospira Inc, Lake Forest, IL 60045, NDC 0409-6625-02",20160601,Class I,Hospira Inc.,D-0865-2016,Letter,73653,,,20160318,60045-2579,Voluntary: Firm initiated,Ongoing,,,,,nan,'SODIUM BICARBONATE','SODIUM BICARBONATE',"'Hospira, Inc.'","'0409-4900', '0409-6625', '0409-6637', '0409-4916', '0409-5534'",'INTRAVENOUS','SODIUM BICARBONATE',"'727995', '792577', '792582', '1868486', '2198792'",'08dbd099-f211-4ec0-95fb-6d4e4fceed26','c814823a-c58b-4697-877c-47af6246f1cd',"'0409-6625-02', '0409-6637-34', '0409-4900-34', '0409-4916-34', '0409-5534-34'",True,nan,nan,nan,'8MDF5V39QO'
United States,South San Francisco,1 Dna Way,"Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted  from the product carton, primary label is correct.",,"3,192 bottles","Lot # 3141989, EXP 08/31/2019",20180213,Distributed throughout the United States,CA,"Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01",20180221,Class III,"Genentech, Inc.",D-0416-2018,Letter,79175,20180906,,20180205,94080-4990,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'NDA017533','KLONOPIN','CLONAZEPAM',"'Genentech, Inc.'","'0004-0058', '0004-0068', '0004-0098'",'ORAL','CLONAZEPAM',"'197527', '197528', '197529', '206157', '206159', '206160'",'69abc49f-2bef-43ee-bbc9-05bca26caefe','542f22e8-dad2-47a8-93b6-30936715d73b',"'0004-0068-01', '0004-0058-01', '0004-0098-01'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','5PE9FDE8GB'
United States,Princeton,107 College Rd E,"Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).",,2770 bags; 277 selling units,"ABD807, exp 05/2020",20190211,Nationwide,NJ,"Levetiracetam in 0.54 % Sodium Chloride Injection 1,500/mg/100mL (15mg/mL), For intravenous Infusion Only, 1 x 100 mL Infusion bag, Manufactured by: Gland Pharma Limited Hyderabad - 500 043, India Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540 UPC 343598637525 ---- NDC 43598-637-52",20190220,Class I,"Dr. Reddy's Laboratories, Inc.",D-0485-2019,Letter,81441,,,20181026,08540-6623,Voluntary: Firm initiated,Ongoing,,,['Decreased Central Nervous System Disorganized Electrical Activity [PE]'],,'ANDA206880','LEVETIRACETAM','LEVETIRACETAM INJECTION',"""Dr.Reddy's Laboratories Inc""","'43598-635', '43598-636', '43598-637'",'INTRAVENOUS','LEVETIRACETAM',"'1193358', '1193360', '1193362'",'1a7d7e03-104e-ff8c-4fbb-0693044bd2fa','0a9234b7-46b1-8e6c-a992-90f86cfb6e00',"'43598-635-52', '43598-635-10', '43598-636-52', '43598-636-10', '43598-637-52', '43598-637-10', '3435986375'",True,'343598637525','N0000008486',nan,'44YRR34555'
United States,Sellersville,650 Cathill Rd,Failed Dissolution Specifications: Product is being recalled due to out of specification dissolution results obtained during routine stability testing.,,"7,579 bottles","34010287A, 34010288A, 34010289A, exp 4/2014; 34011513A, 34011514A, and 34011515A, exp 06/14.",20130807,Nationwide,PA,"Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count bottle, Rx only, TEVA PHARMACEUTICALS USA, NDC 0093-5348-01",20130814,Class II,"Teva Pharmaceuticals USA, Inc.",D-849-2013,Letter,65515,20140827,,20130618,18960-1512,Voluntary: Firm initiated,Terminated,,,,,'ANDA079031','METHYLPHENIDATE HYDROCHLORIDE','METHYLPHENIDATE HYDROCHLORIDE',"'Teva Pharmaceuticals USA, Inc.'","'0093-5346', '0093-5347', '0093-5348'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1806177', '1806179', '1806183'",'1c026445-a471-461a-81d4-15e2646a88db','034fb7cd-e183-475e-8beb-64fd88facc8f',"'0093-5346-01', '0093-5347-01', '0093-5348-01'",True,nan,nan,nan,'4B3SC438HI'
United States,Chestnut Ridge,1 Ram Ridge Rd,Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product,,4506 packs,"AD812, exp 9/2020",20190522,nationwide,NY,"Mycophenolate Mofetil for Injection, USP  500 mg, 4 Single Dose Vials, Rx Only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977  NDC 342023-172-044",20190515,Class I,"Par Pharmaceutical, Inc.",D-1293-2019,Letter,82680,,,20190430,10977-6714,Voluntary: Firm initiated,Ongoing,,,,,'ANDA203575','MYCOPHENOLATE MOFETIL','MYCOPHENOLATE MOFETIL',"'Par Pharmaceutical, Inc.'",'42023-172','INTRAVENOUS','MYCOPHENOLATE MOFETIL','311881','a14f9745-6779-4a14-b696-0ac51d11ade7','35ba0428-e267-49a5-99a9-c58853f7989d','42023-172-04',True,"'0342023172044', '342023172044'",nan,nan,'9242ECW6R0'
United States,Earth City,13600 Shoreline Dr,Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.,,156 bottles,Lot 1111291 Exp. 02/16,20140204,Nationwide and Puerto Rico.,MO,"Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmaceuticals Inc., St. Louis, MO 63045, NDC 0456-3407-33",20140212,Class III,Forest Pharmaceuticals Inc,D-1063-2014,Letter,66838,20140507,,20131113,63045,Voluntary: Firm initiated,Terminated,,,,,'NDA022525','NAMENDA','MEMANTINE HYDROCHLORIDE',"'Allergan, Inc.'","'0456-3400', '0456-3407', '0456-3414', '0456-3421', '0456-3428'",'ORAL',nan,"'996594', '996597', '996603', '996605', '996609', '996611', '996615', '996617', '996624', '996633'",'d92cc2f1-556c-46b0-afc6-4f0fda0bc85c','710f523f-0158-4639-8ce7-57598247d48c',"'0456-3407-33', '0456-3414-11', '0456-3414-63', '0456-3414-33', '0456-3414-90', '0456-3421-33', '0456-3428-11', '0456-3428-63', '0456-3428-33', '0456-3428-90', '0456-3400-29'",True,nan,nan,nan,'JY0WD0UA60'
United States,Cambridge,245 1st St,CGMP Deviations,,"2,170 bottles","Lot Number: 9062, exp. date Feb 2021",20201218,The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.,MA,"Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA  02210, NDC 59922-631-01",20201230,Class II,"Akebia Therapeutics dba Keryx Biopharmaceutials, Inc",D-0170-2021,Letter,86955,,,20201209,02142-1200,Voluntary: Firm initiated,Ongoing,,,,,'NDA205874','AURYXIA','FERRIC CITRATE',"'Akebia Therapeutics, Inc.'",'59922-631','ORAL','TETRAFERRIC TRICITRATE DECAHYDRATE',nan,'198ab4d2-2c3e-49e7-8935-666abff485ad','aadd18e0-3752-11e4-8510-0800200c9a66','59922-631-01',True,nan,nan,nan,'Q91187K011'
United States,Lexington,300 Shire Way,Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules,,"4,520 bottles","Lot Number AE7363A, exp 06/30/2019",20170117,Nationwide and Puerto Rico,MA,"Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81",20170125,Class III,Shire PLC,D-0432-2017,,75880,20180601,,20161202,02421-2101,Voluntary: Firm initiated,Terminated,['Aminosalicylic Acids [CS]'],,,,'NDA020049','PENTASA','MESALAMINE',"'Takeda Pharmaceuticals America, Inc.'","'54092-189', '54092-191'",'ORAL','MESALAMINE',"'206791', '314092', '476362', '580286'",'c69ba849-555c-4b23-8010-e32ab00dee21','e39d9a3d-5d3a-4bb6-aab1-fdbb2a598606',"'54092-189-81', '54092-191-08', '54092-191-12'",True,nan,"'N0000175781', 'M0000971'",'Aminosalicylate EPC','4Q81I59GXC'
United States,Edison,399 Thornall St,Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.,,86 bottles,Lot #0002073  Exp - 12/31/2016,20140731,Nationwide,NJ,"Benicar HCT Tablets (olmesartan medoxomil/hydrochlorothiazide) 40 mg/12.5 mg, 30 count bottles, Rx Only, Manufactured for: Daiichi Sankyo, Inc., Parsippany, NJ 07054 --- NDC 65597-106-30",20140806,Class II,Daiichi Sankyo Pharma Development,D-1507-2014,Telephone,68793,20150316,,20140712,08837-2236,Voluntary: Firm Initiated,Terminated,['Thiazides [CS]'],,['Increased Diuresis [PE]'],,'NDA021532','BENICAR HCT','OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE','Daiichi Sankyo Inc.',"'65597-105', '65597-106', '65597-107'",'ORAL',"'OLMESARTAN MEDOXOMIL', 'HYDROCHLOROTHIAZIDE'","'403853', '403854', '403855', '847042', '847055', '847060'",'746adc8b-b1e5-40f2-ba7c-6a7b1be92214','6bbc032a-3cc4-4b1d-8124-1784214a2821',"'65597-105-07', '65597-105-11', '65597-105-30', '65597-105-90', '65597-106-07', '65597-106-11', '65597-106-30', '65597-106-90', '65597-107-07', '65597-107-11', '65597-107-30', '65597-107-90'",True,"'0365597107304', '0365597106307', '0365597105300'","'N0000175359', 'N0000175419', 'M0471776'",'Thiazide Diuretic EPC',"'0J48LPH2TH', '6M97XTV3HD'"
United States,New York,235 E 42nd St,Failed Dissolution Specifications,,"14,712 bottles","Lot # 03216048A, Exp.  05/18",20170915,Nationwide,NY,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.",20170927,Class III,Pfizer Inc.,D-1163-2017,Letter,77862,20190411,,20170804,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA202100','QUILLIVANT','METHYLPHENIDATE HYDROCHLORIDE',"'NextWave Pharmaceuticals, Inc'","'24478-190', '24478-200', '24478-210', '24478-205'",'ORAL','METHYLPHENIDATE HYDROCHLORIDE',"'1312583', '1312589'",'3c243fb6-41ad-44b8-a644-1d5a9d3df322','e0157005-6e3e-4763-b910-9eb0937608c9',"'24478-190-10', '24478-200-20', '24478-210-30', '24478-205-25'",True,'0324478190101',nan,nan,'4B3SC438HI'
United States,LAKE FOREST,275 NORTH FOREST DRIVE,Presence of Particulate Matter; Potential for particulate matter on the syringe plunger.,,"164,860 syringes","72680LL, Exp. 1DEC2018 (NDC 0409-1782-03); 76510LL, Exp. 1APR2019 (NDC 0409-1782-69)",20180702,"Nationwide in the U.S., Puerto Rico, and Guam",IL,"Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Single-use cartridge syringe, Single unit (NDC 0409-1782-03) and 10 count box (NDC 0409-1782-69), Rx Only, Hospira Inc., Lake Forest, IL",20180613,Class I,"HOSPIRA INC, LAKE FOREST",D-0906-2018,Press Release,80167,20200327,,20180604,60045,Voluntary: Firm initiated,Terminated,,,,,'ANDA070172','NALOXONE HYDROCHLORIDE','NALOXONE HYDROCHLORIDE',"'Hospira, Inc.'",'0409-1782',"'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'NALOXONE HYDROCHLORIDE','1191234','5ac302c7-4e5c-4a38-93ea-4fab202b84ee','b598c237-032d-4bb5-0e92-50eabd863dac',"'0409-1782-03', '0409-1782-69'",True,nan,nan,nan,'F850569PQR'
United States,Lake Forest,275 N Field Dr,Crystallization: Product contains particulate identified to be crystallized active ingredient.,,"373,850 tubes","Lot #: 52610LL, Exp. 01 OCT 2016;  Lot #: 57660LL, Exp. 01 MAR 2017",20160712,Nationwide,IL,"Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only,  Hospira Inc. Lake Forest, IL 60045, NDC 0409-1273-32",20160720,Class II,Hospira Inc.,D-1359-2016,Letter,74399,20180831,,20160623,60045-2579,Voluntary: Firm initiated,Terminated,['Benzodiazepines [CS]'],,,,'ANDA072079','DIAZEPAM','DIAZEPAM',"'Hospira, Inc.'",'0409-1273',"'INTRAMUSCULAR', 'INTRAVENOUS'",'DIAZEPAM','1807459','14233fc1-606a-4e78-8da4-df9eedb1c793','41044928-dd1f-40bf-1fa6-709dff559124',"'0409-1273-03', '0409-1273-32'",True,nan,"'N0000175694', 'M0002356'",'Benzodiazepine EPC','Q3JTX2Q7TU'
United States,Bridgewater,55 Corporate Dr,Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL,,"11,474 cartons of 10 syringes per carton","Lot #: 7S572, Exp. 04/2019",20180105,Distributed nationwide.,NJ,"Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business of Sanofi-aventis, U.S. LLC Bridgewater, NJ 08807, NDC 0955-1012-10",20180117,Class III,Sanofi-Aventis U.S. LLC,D-0153-2018,Letter,78637,20191011,,20171205,08807-1265,Voluntary: Firm initiated,Terminated,,,,,'NDA020164','ENOXAPARIN SODIUM','ENOXAPARIN SODIUM','Winthrop U.S.',"'0955-1003', '0955-1004', '0955-1006', '0955-1008', '0955-1010', '0955-1016', '0955-1012', '0955-1015'",'SUBCUTANEOUS','ENOXAPARIN SODIUM',"'854228', '854235', '854238', '854241', '854245', '854248', '854252', '854255'",'2dbf1997-240d-40e6-8e8e-dba7a82fb088','20635579-c92d-4f6c-a332-1096d51002f2',"'0955-1003-10', '0955-1004-10', '0955-1006-10', '0955-1008-10', '0955-1010-10', '0955-1016-01', '0955-1012-10', '0955-1015-10'",True,nan,nan,nan,'8NZ41MIK1O'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,128 bottles,"Lot #: CY0963, Exp 07/2022",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",20200219,Class II,Pfizer Inc.,D-0842-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Deerfield,1 Baxter Pkwy,"Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed.",,"39,486 containers","Product Code: L5B4826, Lot #: C886820, Exp 11/14",20130801,Nationwide and Puerto Rico,IL,"DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose, 5000 mL container, Rx only, Baxter Healthcare Corporation, Deerfield, IL  60015, Product L5B4826, NDC 0941-0409-07",20130807,Class II,Baxter Healthcare Corp.,D-831-2013,Letter,65784,20140624,,20130724,60015-4625,Voluntary: Firm initiated,Terminated,,,,,'NDA017512','DIANEAL LOW CALCIUM WITH DEXTROSE',"'SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE'",'Baxter Healthcare Corporation',"'0941-0409', '0941-0411', '0941-0413', '0941-0415', '0941-0457', '0941-0459', '0941-0426', '0941-0427', '0941-0429', '0941-0424', '0941-0430', '0941-0433', '0941-0484', '0941-0487', '0941-0490'",'INTRAPERITONEAL',"'DEXTROSE MONOHYDRATE', 'SODIUM CHLORIDE', 'SODIUM LACTATE', 'CALCIUM CHLORIDE', 'MAGNESIUM CHLORIDE'","'799999', '800003', '800057', '800061', '800062', '800064', '800066', '800074', '800111', '800115', '800472', '800474'",'ed5e4e7a-ef2f-4026-a079-260720157706','aa268d3f-7389-4f25-801f-5d4825495f08',"'0941-0411-05', '0941-0411-06', '0941-0411-07', '0941-0411-04', '0941-0411-11', '0941-0413-05', '0941-0413-06', '0941-0413-07', '0941-0413-01', '0941-0413-04', '0941-0415-05', '0941-0415-06', '0941-0415-04', '0941-0415-07', '0941-0415-01', '0941-0409-06', '0941-0409-05', '0941-0409-07', '0941-0409-01', '0941-0457-08', '0941-0457-02', '0941-0457-05', '0941-0457-01', '0941-0459-08', '0941-0459-02', '0941-0459-05', '0941-0459-01', '0941-0426-52', '0941-0426-53', '0941-0426-55', '0941-0427-52', '0941-0427-53', '0941-0427-55', '0941-0429-52', '0941-0429-53', '0941-0429-55', '0941-0424-51', '0941-0424-52', '0941-0424-53', '0941-0424-55', '0941-0430-51', '0941-0430-52', '0941-0430-53', '0941-0430-55', '0941-0433-51', '0941-0433-52', '0941-0433-53', '0941-0433-55', '0941-0484-01', '0941-0487-01', '0941-0490-01'",True,nan,nan,nan,"'LX22YL083G', '02F3473H9O', 'M4I0D6VV5M', '451W47IQ8X', 'TU7HW0W0QT'"
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,36045 bottles,"Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-259-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,202266 units,17112 4/20   17303 10/20   18032 2/21   18072 3/21   18193 8/20   18235 9/21   18285 11/21   19004 1/22   19102 4/22   16260 9/19,20191115,U.S.A. Nationwide,NY,"Altaire Goniotaire Hypromellose 2.5% Opthlamic Demulcent Solution (Sterile), 1/2 fl oz 15 mL, Mfd. by: Altaire Pharmaceuticals, Inc. Aquebogue, NY 11931, NDC 59390-182-13",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0426-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOTAIRE','HYPROMELLOSE 2906 (4000 MPA.S)','Altaire Pharmaceuticals Inc.','59390-182','OPHTHALMIC','HYPROMELLOSE 2906 (4000 MPA.S)','310934','43b938ad-50f8-4ef6-a614-25961d5be07a','9ebedd36-523a-4f92-8fe9-33beaf7288f9','59390-182-13',True,nan,nan,nan,'5EYA69XGAT'
United States,East Windsor,279 Princeton Hightstown Rd,Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).,,4600 Vials,"Lot #CGP190001-A, Exp. 07/31/2020",20200220,"Ohio, Louisiana, Mississippi",NJ,"Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.",20200226,Class III,AuroMedics Pharma LLC,D-0853-2020,Letter,84927,,,20200207,08520-1401,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210244','GLYCOPYRROLATE','GLYCOPYRROLATE','AuroMedics Pharma LLC',"'55150-292', '55150-293', '55150-294', '55150-295'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'eaebb511-1738-4d11-b9bb-317a8d41316a','eaebb511-1738-4d11-b9bb-317a8d41316a',"'55150-292-01', '55150-293-02', '55150-294-05', '55150-295-20'",True,'0355150295203',nan,nan,'V92SO9WP2I'
United States,Broomfield,2555 W Midway Blvd,Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.,,"1,008 bottles","Lot ET5122, Exp. 10/17",20141209,AZ,CO,"Fluoxetine Capsules USP, 20 mg, 100 count bottle, Rx Only, 100 Capsules, Sandoz Inc Princeton, NJ 08540 NDC 0781-2822-01",20141217,Class III,Sandoz Incorporated,D-0291-2015,Letter,69942,20150624,,20141205,80020-1632,Voluntary: Firm initiated,Terminated,,,,,'ANDA075049','FLUOXETINE HYDROCHLORIDE','FLUOXETINE HYDROCHLORIDE','Sandoz Inc',"'0781-2822', '0781-2823', '0781-2824'",'ORAL','FLUOXETINE HYDROCHLORIDE',"'310384', '310385', '313989'",'1c89f15b-eefd-4be2-9055-1374a76669cd','db1c840d-ab22-4a4c-9ced-ae82c869dd9b',"'0781-2823-10', '0781-2823-01', '0781-2823-31', '0781-2822-31', '0781-2822-01', '0781-2822-10', '0781-2824-10', '0781-2824-01', '0781-2824-31'",True,nan,nan,nan,'I9W7N6B1KJ'
United States,Durham,1009 Slater Rd Ste 210B,Labeling; Label Mix-up; correctly labeled 2 mL vials were packaged into blister strips labeled for 1 mL vials,,502 cartons,Lot: M2013645 Exp. Aug. 2022,20210208,Nationwide,NC,"Glycopyrrolate Injection, USP 0.4 mg/2 mL (0.2 mg/mL) 25 x 2 mL Single Dose Vials Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA.  Manufactured by: Intas Pharmaceuticals Limited, Ahmedabad-382 210, India NDC 16729-472-08 (Vial NDC 16729-472-30)",20210217,Class III,"Accord Healthcare, Inc.",D-0250-2021,Letter,87233,,,20210128,27703-8446,Voluntary: Firm initiated,Ongoing,,,,,'ANDA213238','GLYCOPYRROLATE','GLYCOPYRROLATE',"'Accord Healthcare, Inc.,'","'16729-471', '16729-472', '16729-473', '16729-474'","'INTRAMUSCULAR', 'INTRAVENOUS'",'GLYCOPYRROLATE',"'238212', '1731582', '1731590'",'b708bef8-b8e3-7cd1-e053-2995a90a8bdd','871797f0-697a-4a29-a37b-d06219e8f266',"'16729-471-08', '16729-472-08', '16729-473-03', '16729-474-03', '16729-474-05', '16729-472-30'",True,'0316729471633',nan,nan,'V92SO9WP2I'
United States,Columbus,2550 John Glenn Ave Ste A,GMP Deviations: Product bottle may be absent of desiccant.,,"3,720 cartons","Lot 180510, exp 3/31/2020; Lot 181912, exp 4/30/2020",20200218,Nationwide USA,OH,"Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by:  American Health Packaging, Columbus, Ohio 43217.  NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11",20200226,Class II,American Health Packaging,D-0849-2020,Letter,84990,,,20200207,43217-1188,Voluntary: Firm initiated,Ongoing,,,,"['0591-2464', '0591-2465']",'ANDA076470','DESMOPRESSIN ACETATE','DESMOPRESSIN ACETATE','American Health Packaging',"'68084-604', '68084-606'",'ORAL','DESMOPRESSIN ACETATE',"'833008', '849515'",'b102520f-7f80-6fb0-e053-2995a90a136f','043be50e-73b5-45bf-9316-776d4f675170',"'68084-606-11', '68084-606-21', '68084-604-11', '68084-604-21'",nan,nan,nan,nan,'XB13HYU18U'
United States,Detroit,1150 Elijah McCoy Dr,Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide,,"47,813 bottles","JKM2070A  Exp. 07/14, JKM2071A Exp.10/14, JKM2072A Exp. 01/15, JKM2072B Exp. 01/15, JKM6400A Exp. 04/15",20140501,Nationwide,MI,"Children's Cetirizine Hydrochloride Chewable Tablets, 10 mg,  30 count bottle, OTC,  Manufactured by Sun Pharma, Gujarat, India, Distributed Chain Drug Consortium, Boca Raton, FL,  NDC 47335-344-83",20140507,Class III,"Caraco Pharmaceutical Laboratories, Ltd.",D-1297-2014,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",67971,20141007,,20140409,48202-3344,Voluntary: Firm initiated,Terminated,,,,,'ANDA090142','CETIRIZINE HYDROCHLORIDE','CETIRIZINE HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'","'47335-343', '47335-344'",'ORAL','CETIRIZINE HYDROCHLORIDE',"'1014643', '1014674'",'06101976-e656-468e-89f3-d33ccbc1157c','a4758152-97dd-4a27-b4d9-11178654b93e',"'47335-343-83', '47335-343-88', '47335-344-83', '47335-344-88'",True,"'0347335343830', '0347335344837'",nan,nan,'64O047KTOA'
United States,Monroe Township,259 Prospect Plains Road,Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.,Building H,"216,792 bottles","Lot #'s: 64205, 64206, 64200, 64201, 64202, 64203, 64204, 64207, 64264, Exp 05/15; 64265, 64267, 64268, 64270, 64271, Exp 06/15",20140812,Nationwide and Puerto Rico,NJ,"E-Z-HD (barium sulfate) For Suspension (98% w/w), 340 g bottle, Rx Only, Manufactured by E-Z-EM Canada Inc., a subsidiary of E-Z-EM, Inc., Lake Success, NY 11042, NDC 32909-764-01.",20140820,Class III,Bracco Diagnostic Inc,D-1536-2014,Letter,68812,20150630,,20140702,08831,Voluntary: Firm Initiated,Terminated,,['X-Ray Contrast Activity [MoA]'],,,'NDA208036','E-Z-HD','BARIUM SULFATE','E-Z-EM Canada Inc','32909-764','ORAL','BARIUM SULFATE',nan,'b64a3b4e-f3ea-d323-d25e-826ca8af5f78','a4330804-7179-472a-91cb-84bbd5079bb8','32909-764-01',True,nan,"'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','25BB7EKE2E'
United States,Miami,11960 SW 144th St,Defective Delivery System: Products no longer meet the release liner removal specification and/or z-statistic.,,"321,900 patches",Lot: 80433 Exp. 08/17,20170918,Nationwide.,FL,"Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Rx Only Contains: 30 Patches  Manufactured for: Noven Therapeutics, LLC. Miami, FL 33186 By Noven Pharmaceuticals, Inc., Miami, FL 33186, NDC# 68968-5552-3",20170927,Class II,"Noven Pharmaceuticals, Inc.",D-1169-2017,Letter,78021,20200124,,20170830,33186-6109,Voluntary: Firm initiated,Terminated,,,['Central Nervous System Stimulation [PE]'],,'NDA021514','DAYTRANA','METHYLPHENIDATE',"'Noven Therapeutics, LLC'","'68968-5552', '68968-5553', '68968-5554', '68968-5555'",'TRANSDERMAL','METHYLPHENIDATE',"'753436', '753437', '753438', '753439', '753440', '753441', '753442', '753443'",'953cd7a9-7109-48b5-b1dc-f4f38e485fe7','2c312c31-3198-4775-91ab-294e0b4b9e7f',"'68968-5552-3', '68968-5553-3', '68968-5554-3', '68968-5555-3'",True,nan,"'N0000175739', 'N0000175729'",'Central Nervous System Stimulant EPC','207ZZ9QZ49'
United States,Camarillo,5187 Camino Ruiz,Failed Impurities/Degradation Specifications: Out of Specification results obtained for unknown impurities during stability testing by manufacturer,,,"Lot #: GS029673, Exp. Date 5/2021",20210324,Sold to two wholesalers/distributors under government contract located in PA and TX,CA,"Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only, Packaged by GSMS Incorporated, Camarillo, CA 93012-8601 USA, NDC 51407-129-10",20210331,Class II,Golden State Medical Supply Inc.,D-0312-2021,Letter,87566,,,20210319,93012-8601,Voluntary: Firm initiated,Ongoing,,"['Proton Pump Inhibitors [MoA]', 'Cytochrome P450 2C19 Inhibitors [MoA]']",,"['51991-643', '51991-644']",'ANDA203481','OMEPRAZOLE','OMEPRAZOLE','Golden State Medical Supply',"'51407-129', '51407-130'",'ORAL','OMEPRAZOLE',"'198051', '200329'",'b60c6517-b7e9-1f90-e053-2995a90a63ed','7b315cc7-6a5b-38fc-e053-2a91aa0aa19b',"'51407-129-30', '51407-129-90', '51407-129-01', '51407-129-10', '51407-130-30', '51407-130-90', '51407-130-01', '51407-130-05'",nan,nan,"'N0000175525', 'N0000000147', 'N0000182140'",'Proton Pump Inhibitor EPC','KG60484QX9'
United States,Lake Forest,1925 W Field Ct,Failed Stability Specifications; out-of specification value for homogeneity / phase separation.,,a) 62 tubes  and b) 91 tubes,Lot #348716 (exp. 12/2017),20161123,Nationwide,IL,"Desoximetasone Ointment USP, 0.25%, a) 15 g tubes (NDC 61748-206-15 and b) 60 g tubes (NDC 61748-206-60, Marketed by Versapharm Inc., An Akorn Company, Lake Forest, IL, Manufactured by Hi-Tech, Pharmacal Co, Inc., Amityville, NY",20161130,Class II,Akorn Inc,D-0152-2017,Letter,75628,20190510,,20161114,60045-4862,Voluntary: Firm initiated,Terminated,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA201005','DESOXIMETASONE','DESOXIMETASONE','VersaPharm Incorporated','61748-206','TOPICAL','DESOXIMETASONE','197575','4af95c4a-ec3b-44f2-92d5-48069fa4ae19','ee840b15-fda4-4b5c-84e5-a29f65ae2de5',"'61748-206-15', '61748-206-60'",True,nan,"'N0000175576', 'N0000175450'",'Corticosteroid EPC','4E07GXB7AU'
United States,South San Francisco,1 Dna Way,Superpotent Drug: An oversized tablet was found in a bottle.,,748 bottles,"B1009MC, B1009M9, B1009MA; Exp. 02/18  B1009MT 02/19",20170405,NJ and IL,CA,"Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.",20170412,Class II,Genentech Inc.,D-0648-2017,Letter,76726,20170512,,20170313,94080-4990,Voluntary: Firm initiated,Terminated,,,,,'NDA206192','COTELLIC','COBIMETINIB',"'Genentech, Inc.'",'50242-717','ORAL','COBIMETINIB FUMARATE',"'1722370', '1722376'",'f49e84e4-2b10-4567-b505-7ceabc1c32ee','c387579e-cee0-4334-bd1e-73f93ac1bde6',"'50242-717-01', '50242-717-86'",True,nan,nan,nan,'6EXI96H8SV'
India,Karodi,H - 14/2 Plot,Failed Impurities/Degradation Specifications,Biotech Park,"17,628 tablets",Batch# DR10447 (Exp: 4/19); Batch# DR10996 (Exp: 10/19); Batch# DS10201 (Exp: 2/20); and Batch# DR10319 (Exp: 3/20).,20180709,Nationwide.,,Enalapril Maleate Tablets USP; 2.5 mg NDC code 64679-923-03. 1000 Tablets HDPE container pack with Non CRC cap and 2 desiccants further packed in E-flute cartons.,20180718,Class III,Wockhardt Limited,D-0913-2018,,80356,20200413,,20180619,,,Terminated,,,,,'ANDA075483','ENALAPRIL MALEATE','ENALAPRIL MALEATE','Wockhardt USA LLC.',"'64679-923', '64679-924', '64679-925', '64679-926'",'ORAL','ENALAPRIL MALEATE',"'858804', '858810', '858813', '858817'",'04c894d4-a77a-4f2a-9286-d8c0838181eb','d41d6d19-086c-4e17-814c-6fd6f3e81e24',"'64679-923-07', '64679-923-01', '64679-923-02', '64679-923-03', '64679-923-09', '64679-923-10', '64679-924-07', '64679-924-01', '64679-924-02', '64679-924-03', '64679-924-09', '64679-924-10', '64679-925-07', '64679-925-01', '64679-925-02', '64679-925-03', '64679-925-09', '64679-925-10', '64679-926-07', '64679-926-01', '64679-926-02', '64679-926-03', '64679-926-09', '64679-926-10'",True,"'0364679923023', '0364679924020', '0364679926031'",nan,nan,'9O25354EPJ'
United States,East Windsor,279 Princeton Hightstown Rd,Lack of Assurance of Sterility; confirmed customer report of a leaking bags and mold found between the outer bag and the overwrap,,46824 bags,"Lot/Batch #'s:    CLF160002, CLF160004, CLF160005 exp May 2018; CLF160006, CLF160007 exp June 2018; CLF170027 exp July 2019; CLF170029 exp August 2019",20180503,US Nationwide,NJ,"Levofloxacin in 5% Dextrose Injection, 250 mg Levofloxacin (5 mg/mL) in 50 mL of 5% Dextrose, For Intravenous Infusion, Rx only, Manufactured By: Aurobindo Pharma Limited IDA Pashamylaram - 502307, India, Manufactured for: AuroMedics Pharma, LLC, NDC 55150-243-46.",20180509,Class II,AuroMedics Pharma LLC,D-0704-2018,Letter,79772,,,20180327,08520-1401,Voluntary: Firm initiated,Ongoing,['Quinolones [CS]'],,,,'ANDA206919','LEVOFLOXACIN','LEVOFLOXACIN','AuroMedics Pharma LLC',"'55150-243', '55150-244', '55150-245'",'INTRAVENOUS','LEVOFLOXACIN',"'1665497', '1665507', '1665515'",'e50aa3f8-7411-411f-b577-fd3ecddcb12f','7d3f83bf-2db7-4657-9538-406adf321ad5',"'55150-243-46', '55150-244-47', '55150-245-52'",True,'0355150244478',"'N0000175937', 'M0023650'",'Quinolone Antimicrobial EPC','6GNT3Y5LMF'
United States,Irvine,2525 McGaw Ave,Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.,,"22,584 units","Lot# H3E507, Exp 11/14",20140425,"Nationwide, Puerto Rico and Spain",CA,"Cefoxitin for Injection and Dextrose Injection, 1 g in Duplex, 50 mL Container, Catalog No. 3123-11, For IV Use Only, Single Use, Sterile, Rx Only, B Braun Medical Inc, Irvine CA 92614-5895, NDC 0264-3123-11",20140507,Class I,B. Braun Medical Inc,D-1264-2014,Letter,66913,20141204,,20131121,92614-5841,Voluntary: Firm initiated,Terminated,,,,,'NDA065214','CEFOXITIN AND DEXTROSE','CEFOXITIN SODIUM','B. Braun Medical Inc.',"'0264-3123', '0264-3125'",'INTRAVENOUS','CEFOXITIN SODIUM',"'1665102', '1665107'",'77411b80-ddbd-4494-8206-40b163a28fc7','6c7e9485-1ede-411c-8c46-911439332864',"'0264-3123-11', '0264-3125-11'",True,nan,nan,nan,'Q68050H03T'
United States,Camarillo,5187 Camino Ruiz,Presence of Foreign Substance: Presence of hair.,,"1,165 Bottles","Lot # GS007849, Expiry: 02/2017",20150909,U.S. Including: GA.,CA,"METHOCARBAMOL TABLETS, USP 500 mg, 500 Count Bottles, Rx Only. Manufactured by AustarPharma LLC, Edison, NJ 08837, USA, Packaged by GSMS Incorporated, Camarillo, CA 93012, USA, NDC: 60429-118-05.",20150916,Class III,Golden State Medical Supply Inc.,D-1426-2015,Letter,71921,20151127,,20150811,93012-8601,Voluntary: Firm initiated,Terminated,,,['Centrally-mediated Muscle Relaxation [PE]'],,'ANDA200958','METHOCARBAMOL','METHOCARBAMOL','Golden State Medical Supply',"'60429-118', '60429-119'",'ORAL','METHOCARBAMOL',"'197943', '197944'",'9e6ae6f5-85f0-43a6-e053-2a95a90a6641','58f867fd-cad0-4bef-9bd6-9c401bda2120',"'60429-119-01', '60429-119-05', '60429-118-05', '60429-118-01'",True,nan,"'N0000175730', 'N0000175737'",'Muscle Relaxant EPC','125OD7737X'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","2,853,500 Caplets","Lot #: HH6001, HH6002, Exp 04/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 200 mg, 6 x 6500 Caplets (Capsule-Shaped Tablets) bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-117-30.",20180131,Class II,Marksans Pharma Inc.,D-0235-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA091239','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-114', '25000-117'",'ORAL','IBUPROFEN','310965','d833cc00-92b7-4b2a-8ca2-973d2ce70df3','3c8df1e5-61bc-4e70-b6b9-8973986ad589',"'25000-114-03', '25000-114-14', '25000-114-20', '25000-114-30', '25000-114-98', '25000-114-93', '25000-114-70', '25000-114-71', '25000-117-03', '25000-117-14', '25000-117-20', '25000-117-30', '25000-117-98', '25000-117-93', '25000-117-69'",True,"'0325000117146', '0325000117030', '0325000114145', '0325000114039'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Basking Ridge,150 Allen Rd Ste 102,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.",,"39,432 bottles","Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021",20191002,Nationwide USA and Puerto Rico,NJ,"Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for:  Torrent Pharma Inc., Basking Ridge, NJ 07920.  NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10",20191009,Class II,Torrent Pharma Inc.,D-0122-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83840,,,20190919,07920-3856,Voluntary: Firm initiated,Ongoing,,,,,'ANDA090467','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Torrent Pharmaceuticals Limited',"'13668-113', '13668-409', '13668-115'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'947c4505-9310-2ba5-e053-2a95a90aa705','4c2347db-79a3-4279-87f8-9fa91e6d00e3',"'13668-113-90', '13668-113-10', '13668-113-74', '13668-409-30', '13668-409-90', '13668-409-10', '13668-409-74', '13668-115-30', '13668-115-90', '13668-115-10', '13668-115-74'",True,"'0313668113907', '0313668409901', '0313668115901'",nan,nan,'3ST302B24A'
United States,Columbus,2550 John Glenn Ave,Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from an  unapproved source.,Suite A,"8,570 blister packs","Lot 120757, Exp. 02/14; Lot 121104, Exp 03/14; Lot 122055, Exp 05/14; Lot  123038, Exp  07/14;  Lot 125115, Exp 11/14",20140403,Nationwide,OH,"HydrOXYzine HCl Tablets, USP  50 mg, 100 Tablet Blister, Rx only Mfd by: KVK-TECH, INC. Newtown, PA 18940, NDC 68084-255-01",20140409,Class II,American Health Packaging,D-1189-2014,Letter,67881,20150401,,20140131,43217-1188,Voluntary: Firm initiated,Terminated,,,,"['10702-010', '10702-011', '10702-012']",'ANDA040786','HYDROXYZINE HYDROCHLORIDE','HYDROXYZINE HYDROCHLORIDE','American Health Packaging',"'68084-253', '68084-254', '68084-255'",'ORAL','HYDROXYZINE HYDROCHLORIDE',"'995218', '995258', '995281'",'88d91b0c-0d89-5abd-e053-2a95a90afd37','7d4593dd-6cf6-45c2-9823-739bee485bb8',"'68084-253-11', '68084-253-01', '68084-254-11', '68084-254-01', '68084-255-11', '68084-255-01'",nan,nan,nan,nan,'76755771U3'
United States,Morristown,36 Columbia Rd,"Labeling: Label Mix-up: This recall was initiated after identifying that the label statement on the blister strip regarding the maximum number of capsules/caplets that should be taken within a 24-hour period, does not match the statement on the carton.",,"119,412 cartons","NAA04K6 Exp. 09/13, NAA055P Exp. 09/13, NAA05PA Exp. 09/13",20120719,Product was distributed to 93 retail accounts/customers.,NJ,"Midol Complete, Acetaminophen, Caffeine, Pyrilamine Maleate, Gelcaps 24 ct. blister, OTC,  Distributed by Bayer Health Care, Morristown, NJ 07962   NDC 0280-8015-24",20120725,Class III,"Bayer Healthcare, LLC",D-1423-2012,Letter,61948,20140327,,20120426,07960-4526,Voluntary: Firm initiated,Terminated,['Xanthines [CS]'],,['Central Nervous System Stimulation [PE]'],,'part343','MIDOL COMPLETE','MIDOL COMPLETE','Bayer HealthCare LLC','0280-8015','ORAL',"'CAFFEINE', 'PYRILAMINE MALEATE', 'ACETAMINOPHEN'",'1597298','5de37e93-808b-0594-e053-2991aa0a1e32','0a4477ce-0a02-197d-e054-00144ff88e88','0280-8015-24',True,'0000000000000',"'N0000175739', 'N0000175729', 'N0000175790', 'M0023046'","'Central Nervous System Stimulant EPC', 'Methylxanthine EPC'","'3G6A5W338E', 'R35D29L3ZA', '362O9ITL9D'"
United States,Lake Forest,600 N Field Dr Bldg J45,"Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.",,"100,200 Vials","Lot #: 44-359-DK, Exp 08/01/2016",20150918,Nationwide,IL,"1% Lidocaine HCl Injection, USP, 10 mg/mL, 30 mL Vial, Single-dose Preservative Free, Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-4279-02",20150930,Class II,"Hospira, Inc.",D-1815-2015,Letter,72072,,,20150825,60045,Voluntary: Firm Initiated,Ongoing,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Lake Forest,275 N Field Dr,Presence of Particulate Matter: Confirmed customer complaint of discolored solution with visible metal particles embedded in the glass vial and visible in the solution.,,"40,730 vials","Lot # 33-545-DD, Exp. 09/15",20141001,Nationwide,IL,"Marcaine (bupivacaine HCl) injection, USP, 0.5%, Preservative-Free, 30 mL (150 mg) Single-dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045   NDC 0409-1560-29",20141008,Class I,Hospira Inc.,D-0002-2015,Press Release,68579,20170403,,20140617,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'NDA016964','MARCAINE','BUPIVACAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-1559', '0409-1560', '0409-1582', '0409-1587', '0409-1610', '0409-1746', '0409-1749', '0409-1752', '0409-1755'","'EPIDURAL', 'INFILTRATION', 'INTRACAUDAL', 'PERINEURAL'",'BUPIVACAINE HYDROCHLORIDE',"'1012377', '1012381', '1012384', '1012388', '1012396', '1012400', '1012404', '1012406', '1672917', '1672919', '1673242', '1673243', '1724786', '1724787', '1724794', '1724796', '1724880', '1724884', '1725044', '1725046', '1725078', '1725079', '1725082', '1725083', '1867594', '1867596', '1867612', '1867614'",'aa4999e8-239f-40c0-a9f5-5e815c255444','67578b56-7540-487e-1fba-481255620e78',"'0409-1559-18', '0409-1559-10', '0409-1559-19', '0409-1559-30', '0409-1560-18', '0409-1560-10', '0409-1560-19', '0409-1560-29', '0409-1582-18', '0409-1582-10', '0409-1582-19', '0409-1582-29', '0409-1587-50', '0409-1610-50', '0409-1746-70', '0409-1746-10', '0409-1746-71', '0409-1746-30', '0409-1749-70', '0409-1749-10', '0409-1749-71', '0409-1749-29', '0409-1752-50', '0409-1755-50'",True,nan,nan,nan,"'30Q7KI53AK', '7TQO7W3VT8'"
United States,Chestnut Ridge,1 Ram Ridge Rd,Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg,,13008 bottles,"Lot #: 8672518, Exp 12/21",20200318,U.S.A. Nationwide,NY,"PrediniSONE Tablets, USP 5 mg, 48-count bottle,  Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977,  NDC 0603-5337-31",20200325,Class III,Par Pharmaceutical Inc.,D-1035-2020,Letter,85136,,,20200304,10977-6714,Voluntary: Firm initiated,Ongoing,,['Corticosteroid Hormone Receptor Agonists [MoA]'],,,'ANDA040584','PREDNISONE','PREDNISONE','Par Pharmaceutical',"'0603-5335', '0603-5336', '0603-5337', '0603-5338', '0603-5339'",'ORAL','PREDNISONE',"'198144', '198145', '198146', '312615', '312617', '763179', '763181', '763183', '763185'",'bf179c06-4480-4f07-8e38-10e8fddc2ed6','10fe5a3b-84dc-4600-87c2-b80c97ce18cf',"'0603-5335-21', '0603-5335-32', '0603-5336-21', '0603-5337-21', '0603-5337-32', '0603-5337-15', '0603-5337-31', '0603-5338-21', '0603-5338-28', '0603-5338-32', '0603-5338-15', '0603-5338-31', '0603-5339-21', '0603-5339-28', '0603-5339-32'",True,"'0306035338218', '0306035337310', '0306035335217', '0306035338157', '0306035338287', '0306035339215', '0306035339284', '0306035335323', '0306035338324', '0306035336214', '0306035339321', '0306035337211', '0306035337327'","'N0000175576', 'N0000175450'",'Corticosteroid EPC','VB0R961HZT'
United States,Princeton,100 College Rd W,Cross Contamination with Other Products,,23053 bottles,"Lot #: JA7319, JA 7320, JA7321, Exp.  03/2020",20181120,Nationwide within the United States,NJ,"Nitrofurantoin Capsules, USP (Monohydrate/Macrocrystals) 100 mg, 100-count bottoles, Rx Only, Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Sandoz Inc. Princeton, NJ 08540,NDC 16714-439-01",20181121,Class III,Sandoz Inc,D-0262-2019,Letter,81457,20201002,,20181102,08540-6604,Voluntary: Firm initiated,Terminated,['Nitrofurans [CS]'],,,,'ANDA077066','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)','Northstar RxLLC','16714-439','ORAL',"'NITROFURANTOIN MONOHYDRATE', 'NITROFURANTOIN'",'1648755','f387af08-e722-4460-951e-eea7a99e14a6','d0dbfce6-d5ea-41d8-b568-c021bc77457b',"'16714-439-01', '16714-439-02'",True,'0316714439013',"'N0000175494', 'M0014892'",'Nitrofuran Antibacterial EPC',"'E1QI2CQQ1I', '927AH8112L'"
United States,Cranbury,270 Prospect Plains Rd,Presence of Foreign Substance: consumer complaint for foreign matter embedded in the tablet identified as a broken piece of wire rope from the manufacturing equipment.,,"22,915 bottles","Lot #: JKR5219A, JKR5200A, JKR5220A, JKR5221A, JKR5222A, Exp 03/18",20170301,Nationwide in the USA and Puerto Rico.,NJ,"Alfuzosin Hydrochloride Extended-release Tablets, 10 mg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, Gujarat, India, NDC 47335-956-88.",20170308,Class II,"Sun Pharmaceutical Industries, Inc.",D-0502-2017,Letter,76543,20180629,,20170105,08512-3605,Voluntary: Firm initiated,Terminated,,,,,'ANDA079057','ALFUZOSIN HYDROCHLORIDE','ALFUZOSIN HYDROCHLORIDE',"'Sun Pharmaceutical Industries, Inc.'",'47335-956','ORAL','ALFUZOSIN HYDROCHLORIDE','861132','ddbdcf2d-400b-461e-a3d3-0af2482e1c9e','d2af616e-673a-4fdd-ace8-db2d0f154604',"'47335-956-83', '47335-956-81', '47335-956-88', '47335-956-08', '47335-956-18'",True,'0347335956818',nan,nan,'75046A1XTN'
United States,Morgantown,781 Chestnut Ridge Rd,"CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.",,"23,478 bottles","Lot # 3066051, exp. date 3/2019",20181214,Product was distributed throughout the United States.,WV,"Amlodipine and Valsartan Tablets, USP, 5 mg/160 mg, 30-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A., NDC 0378-1721-93.",20181219,Class II,Mylan Pharmaceuticals Inc.,D-0311-2019,Press Release,81613,,,20181120,26505-2730,Voluntary: Firm initiated,Ongoing,,['Angiotensin 2 Receptor Antagonists [MoA]'],,,'ANDA090483','AMLODIPINE AND VALSARTAN','AMLODIPINE AND VALSARTAN','Mylan Pharmaceuticals Inc.',"'0378-1721', '0378-1722', '0378-1723', '0378-1724'",'ORAL',"'AMLODIPINE BESYLATE', 'VALSARTAN'","'722126', '722131', '722134', '722137'",'f4a12269-d473-43e9-b329-48724d619126','aa7e7d95-520a-461c-b1b3-e588aeb6a613',"'0378-1721-93', '0378-1722-93', '0378-1723-93', '0378-1724-93'",True,"'0303781721936', '0303781722933', '0303781723930', '0303781724937'","'N0000000070', 'N0000175561'",'Angiotensin 2 Receptor Blocker EPC',"'80M03YXJ7I', '864V2Q084H'"
United States,East Brunswick,1 Tower Center Blvd Ste 1700,"CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer",,3012 bottles,Lot CLO17007A    Lot CLO17008A       Lot CLO17009A ; Exp 11/2019,20190521,Nationwide,NJ,"Losartan Potassium Tablets, USP 50 mg 1000 film coated tablets Rx Only  Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108  SIDCO Pharmaceutical Complex, Alathur, Kanchipuram - 603 110, Tamilnadu, India.   Manufactured for: Heritage Pharmaceuticals Inc., East Brunswick, NJ 08816. 1-866-901-DRUG (3784)  NDC 23155-645-10",20190529,Class II,"Heritage Pharmaceuticals, Inc.",D-1287-2019,Press Release,82782,20201116,,20190503,08816-1145,Voluntary: Firm initiated,Terminated,,,,,'ANDA090382','LOSARTAN POTASSIUM','LOSARTAN POTASSIUM','Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.',"'23155-644', '23155-645', '23155-646'",'ORAL','LOSARTAN POTASSIUM',"'979480', '979485', '979492'",'ab9a41fe-7b40-a543-e053-2995a90acab6','a3f034a4-c65b-4f53-9f2e-fef80c260b84',"'23155-644-03', '23155-644-09', '23155-644-10', '23155-645-03', '23155-645-09', '23155-645-10', '23155-646-03', '23155-646-09', '23155-646-10'",True,nan,nan,nan,'3ST302B24A'
United States,WILMINGTON,1800 CONCORD PIKE,Adulterated Presence of Foreign Tablets/Capsules: Some bottles may contain a small number of Nexium 20 mg capsules intended for the Japanese market in addtion to Nexium 40 mg capsules.,,"2,556 bottles","Lot #: H008328, Exp 11/14",20120711,Nationwide.,DE,"Nexium (esomeprazole magnesium) Delayed-Release Capsules, 40 mg, 1000-count bottle, Rx only, Manufactured for: AstraZeneca LP, Wilmington, DE  19850; By: AstraZeneca AB, S-151 85 Sodertalje, Sweden, NDC 0186-5040-85, UPC 3 0186-5040-85 0.",20120718,Class III,ASTRA ZENECA Lp,D-1410-2012,Letter,62439,20130411,,20120702,19803-2902,Voluntary: Firm initiated,Terminated,,,,,'NDA022101','NEXIUM','ESOMEPRAZOLE MAGNESIUM','AstraZeneca Pharmaceuticals LP',"'0186-4010', '0186-5020', '0186-4020', '0186-4040', '0186-5040', '0186-4025', '0186-4050'",'ORAL','ESOMEPRAZOLE MAGNESIUM',"'606726', '606728', '606730', '606731', '692576', '692578', '861568', '861570', '861576', '861583', '1297658', '1297660', '1297761', '1297763'",'3797ceb7-550b-4e9a-8314-8e1e4995360b','f4853677-1622-4037-688b-fdf533a11d96',"'0186-5020-31', '0186-5020-54', '0186-5020-82', '0186-4010-01', '0186-4010-02', '0186-4020-01', '0186-4040-01', '0186-4040-02', '0186-5040-31', '0186-5040-35', '0186-5040-55', '0186-5040-85', '0186-5040-54', '0186-5040-82', '0186-5040-05', '0186-4025-01', '0186-4025-02', '0186-4050-01'",True,'301865040850',nan,nan,'R6DXU4WAY9'
United States,Spring Valley,1 Ram Ridge Rd,Failed Impurities/Degradation Specifications: Out of specification for impurities.,,"a) 162,385 Bottles; b) 6949 Bottles","a)  Lot #: 24820001, Expiry: NOV 2015; Lot #: 25783601, Expiry: OCT 2016; Lot #: 25783801, Expiry: OCT 2016;  Lot #: 26731201, Expiry: AUG 2017;  Lot #: 26762002, Expiry: FEB 2018. b) Lot #:  26683201, Expiry: AUG 2017; Lot#: 26762001, Expiry: FEB 2018.",20151113,U.S. Nationwide including Puerto Rico,NY,"Meclizine Hydrochloride Tablets, USP, 12.5 mg Tablets, Packaged in a) 100 Ct Bottles (NDC: 49884-034-01) and b) 1000 Ct Bottles (NDC: 49884-034-10), Rx only. Par Pharmaceutical Companies, Inc., Spring Valley, NY 10977.",20151125,Class III,Par Pharmaceutical Inc.,D-0233-2016,Letter,72476,20170420,,20151026,10977-6714,Voluntary: Firm initiated,Terminated,,,,,'ANDA087127','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCHLORIDE',"'Par Pharmaceutical, Inc.'","'49884-034', '49884-035'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'d687dbbb-40ef-4614-93e6-c20366f3607d','74d48c40-b484-402d-8ce3-5c60f2370ed6',"'49884-035-01', '49884-035-10', '49884-034-01', '49884-034-10'",True,"'0349884034016', '0349884035013'",nan,nan,'HDP7W44CIO'
United States,Princeton,"821 Alexander Rd, Ste 204",Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.,120 W 7th St   Suite,3860 syringes,"Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021",20191009,Nationwide in the USA,NJ,"Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.",20191016,Class II,GUERBET LLC,D-0137-2020,Letter,83798,,,20190913,08540-0000,Voluntary: Firm initiated,Ongoing,,['X-Ray Contrast Activity [MoA]'],,,'NDA019710','OPTIRAY','IOVERSOL','Liebel-Flarsheim Company LLC',"'0019-1323', '0019-1333', '0019-1332', '0019-1324'","'INTRA-ARTERIAL', 'INTRAVENOUS'",'IOVERSOL',nan,'e4a36c3b-837e-48da-abb4-498cdf3c7079','549d38db-d4ed-4708-8f76-7cdaa157063f',"'0019-1333-06', '0019-1333-11', '0019-1333-16', '0019-1333-21', '0019-1333-75', '0019-1333-77', '0019-1333-91', '0019-1333-83', '0019-1333-81', '0019-1333-78', '0019-1333-52', '0019-1333-95', '0019-1333-90', '0019-1333-87', '0019-1333-55', '0019-1333-85', '0019-1333-00', '0019-1333-27', '0019-1323-06', '0019-1323-11', '0019-1323-16', '0019-1323-21', '0019-1323-73', '0019-1323-75', '0019-1323-77', '0019-1323-91', '0019-1323-83', '0019-1323-81', '0019-1323-70', '0019-1323-78', '0019-1323-52', '0019-1323-95', '0019-1323-90', '0019-1323-87', '0019-1323-55', '0019-1323-85', '0019-1323-00', '0019-1323-27', '0019-1323-02', '0019-1323-04', '0019-1332-06', '0019-1332-11', '0019-1332-16', '0019-1332-21', '0019-1332-75', '0019-1332-78', '0019-1332-91', '0019-1332-83', '0019-1332-90', '0019-1332-00', '0019-1324-06', '0019-1324-11', '0019-1324-21', '0019-1324-75', '0019-1324-81', '0019-1324-78', '0019-1324-87', '0019-1324-27'",True,"'0300191323873', '0300191324870', '0300191332905', '0300191333872'","'N0000180185', 'N0000010258'",'Radiographic Contrast Agent EPC','N3RIB7X24K'
United States,Cherry Hill,2 Esterbrook Ln,Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.,,"2,100,646 Vials","a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.",20201120,Nationwide in the U.S.,NJ,"Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.",20201125,Class II,Hikma Pharmaceuticals USA Inc.,D-0101-2021,Letter,86685,,,20201103,08003-4002,Voluntary: Firm initiated,Ongoing,,,,,'ANDA201833','SODIUM CHLORIDE','SODIUM CHLORIDE','West-Ward Pharmaceuticals Corp.',"'0641-0497', '0641-6144'","'INTRAMUSCULAR', 'INTRAVENOUS', 'SUBCUTANEOUS'",'SODIUM CHLORIDE',"'1807636', '1807637'",'8b0a93ae-1bcc-4f84-921a-d959a4fe161e','e5ee8caa-b6ca-45ba-98fb-8305e6282141',"'0641-0497-17', '0641-0497-25', '0641-6144-01', '0641-6144-25'",True,nan,nan,nan,'451W47IQ8X'
United States,Brookhaven,50 Horseblock Rd,CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API,,,AR172033B 11/2019  AR180024A 12/2019  AR180025A 12/2019  AR180118A 12/2019  AR180119A 12/2019  AR180519A 3/2020  AR180615A 3/2020  AR181795A 11/2020  AR181921B 12/2020  AR190705A 4/2021  AR172029A 11/2019  AR172030A 11/2019  AR180021A 12/2019  AR180022A 12/2019  AR180023A 12/2019  AR180123A 12/2019  AR180144A 1/2020  AR180145A 1/2020  AR180146A 1/2020  AR180147A 1/2020  AR180402A 2/2020  AR180465A 2/2020  AR180466A 2/2020  AR180467A 2/2020  AR180468A 2/2020  AR180613A 3/2020  AR181156A 7/2020  AR181157A 7/2020  AR190418B 2/2021  AR171800A 11/2019  AR171801A 11/2019  AR171802A 11/2019  AR171803A 11/2019  AR171804A 11/2019  AR171931A 11/2019  AR171932A 11/2019  AR171933A 11/2019  AR171934A 11/2019  AR171935A 11/2019  AR171936A 11/2019  AR171937A 11/2019  AR172026A 11/2019  AR172027A 11/2019  AR172028A 11/2019  AR172031A 11/2019  AR172032A 11/2019  AR172033A 11/2019  AR172034A 11/2019  AR172035A 11/2019  AR180030A 12/2019  AR180031A 12/2019  AR180032A 12/2019  AR180033A 12/2019  AR180034A 12/2019  AR180113A 12/2019  AR180114A 12/2019  AR180115A 12/2019  AR180117A 12/2019  AR180120A 12/2019  AR180121A 12/2019  AR180122A 12/2019  AR180148A 1/2020  AR180198A 1/2020  AR180199A 1/2020  AR180200A 1/2020  AR180201A 1/2020  AR180202A 1/2020  AR180257A 1/2020  AR180258A 1/2020  AR180335A 2/2020  AR180336A 2/2020  AR180337A 2/2020  AR180338A 2/2020  AR180339A 2/2020  AR180374A 2/2020  AR180375A 2/2020  AR180376B 2/2020  AR180403A 2/2020  AR180404A 2/2020  AR180405A 2/2020  AR180406A 2/2020  AR180424A 2/2020  AR180486A 3/2020  AR180487A 3/2020  AR180488A 3/2020  AR180515A 3/2020  AR180516A 3/2020  AR180517A 3/2020  AR180518A 3/2020  AR180638A 3/2020  AR180640A 4/2020  AR180641A 4/2020  AR181920A 12/2020  AR181921A 12/2020  AR190414B 2/2021  AR190415A 2/2021  AR190416A 2/2021  AR190417A 2/2021  AR190418A 2/2021  AR190543A 3/2021  AR190544A 3/2021  AR190545A 3/2021,20191209,Product was distributed throughout the United States.,NY,"Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25).",20191218,Class II,"Amneal Pharmaceuticals, Inc.",D-0613-2020,Press Release,84353,,,20191122,11719-9509,Voluntary: Firm initiated,Ongoing,,,,,'ANDA077824','RANITIDINE','RANITIDINE','Amneal Pharmaceuticals LLC',"'65162-253', '65162-254'",'ORAL','RANITIDINE HYDROCHLORIDE',"'198191', '198193'",'21e115aa-b8fc-46fd-b15c-1bcad41f4604','9f416ce0-012f-4194-9382-74ac71e4b2a9',"'65162-253-06', '65162-253-10', '65162-253-11', '65162-253-18', '65162-253-50', '65162-254-03', '65162-254-10', '65162-254-11', '65162-254-25', '65162-254-30'",True,"'0365162254037', '0365162253061'",nan,nan,'BK76465IHM'
United States,Livonia,17177 N Laurel Park Dr Ste 233,Failed Dissolution Specifications: Out of specification for dissolution.,,841 cartons,"Lots: T02520, T02637, exp 02/2021",20201201,Nationwide,MI,"Aripiprazole Tablets, USP, 15 mg, 30 tablets per unit dose carton, Rx Only, Manufactured by: Apotex, Inc, Toronto, Ontario Canada M9L 1T9, Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6512-04",20201209,Class II,The Harvard Drug Group,D-0114-2021,Letter,86787,,,20201118,48152-3951,Voluntary: Firm initiated,Ongoing,,,,"['60505-3075', '60505-2673', '60505-2674', '60505-2675', '60505-2676', '60505-2677']",'ANDA078583','ARIPIPRAZOLE','ARIPIPRAZOLE','Major Pharmaceuticals',"'0904-6509', '0904-6510', '0904-6511', '0904-6512', '0904-6513', '0904-6514'",'ORAL','ARIPIPRAZOLE',"'349490', '349545', '349547', '349553', '402131', '602964'",'143dfc7c-a38f-4da8-a28c-2863670945d5','3279b9dc-8efd-463b-8f15-e26162ed78e3',"'0904-6509-04', '0904-6510-61', '0904-6510-06', '0904-6511-61', '0904-6511-06', '0904-6512-04', '0904-6513-04', '0904-6514-04'",nan,nan,'N0000175430','Atypical Antipsychotic EPC','82VFR53I78'
United States,Lexington,65 Hayden Ave,Presence of Particulate Matter: Potential presence of glass particulate matter in the vials.,,"4,966,575 Vials","Lot #: 081753F, 081803F, 081853F, Exp 08/2014; 090103F, 090153F, 090303F, 090353F, 090403F, 090453F, 090503F, Exp 09/2014; 100503F, 100553F, 100603F, 100653F, 100703F, 100753F, 100803F, 100853F, 100903F, Exp 10/2014; 101303F, 110303F, 110353F, 110403F, 110453F,   110503F, 110603F, 110653F, 110703F, Exp 11/2014; 120303F, 120353F, 120403F, 120453F, 120503F, 120553F, 120653F, 120703F, Exp 12/2014; 140453F, Exp 02/2015; 140603F, 140653F, 140703F, 150203F, 150253F, 150303F, 150353F, 150403F, 150453F, Exp 03/2015; 160853F, 160903F,   160953F, 161003F, 161053F, 161103F, Exp 05/2015; 181003F, 181053F, 181103F, 181153F, 181603F, 181653F, 181703F, Exp 06/2015; 201503F, 201553F, 201603F, Exp 08/2015; 201753F, 210453F, Exp 09/2015; 210503F, 210553F, 210603F, 210653F, 220353F, 220403F, 220453F, Exp 10/2015; 220503F, 220553F, 220603F, 230303F, 230353F, 230403F, 230453F, 230503F, 230553F, Exp 11/2015; 240053F, 240153F, 240203F, 240253F, 240303F, Exp 12/2015; 260603F, 260653F, 260703F, Exp 02/2016; 271303F, 271353F, 271403F, 271453F, 271503F, 271553F, Exp 03/2016; 280203F, 280253F, 280303F, 280403F, Exp 04/2016; 290203F, 290303F, 290353F, Exp 06/2016.",20141001,"Nationwide   Foreign:  Israel, Taiwan",MA,"CUBICIN (daptomycin for injection), 500 mg single-use vial, Rx only, Manufactured for: Cubist Pharmaceuticals, Inc., Lexington, MA 02421, NDC 67919-011-01, UPC 3 67919-011-01 6.",20141008,Class I,"Cubist Pharmaceuticals, Inc.",D-0001-2015,Press Release,68969,20160629,,20140801,02421-7994,Voluntary: Firm Initiated,Terminated,['Lipopeptides [CS]'],,,,'NDA021572','CUBICIN','DAPTOMYCIN','Merck Sharp & Dohme Corp.','67919-011','INTRAVENOUS','DAPTOMYCIN',"'403920', '404652'",'39ec2191-a01c-4860-a5f0-42c48b3ffef5','a7975871-46a6-4e9b-a8b5-38bfcb465f0e','67919-011-01',True,'367919011016',"'N0000175509', 'M0519359'",'Lipopeptide Antibacterial EPC','NWQ5N31VKK'
United States,Morgantown,781 Chestnut Ridge Rd,Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..,,"3,048 bottles","Lot # ZRMB11004, Exp 09/13",20130530,Nationwide,WV,"Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for:  Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A.  Made in India",20130605,Class II,Mylan Pharmaceuticals Inc.,D-500-2013,Letter,65008,20140414,,20130422,26505-2730,Voluntary: Firm initiated,Terminated,,,,,'ANDA078881','ROPINIROLE','ROPINIROLE','Mylan Pharmaceuticals Inc.',"'0378-5501', '0378-5525', '0378-5550', '0378-5502', '0378-5503', '0378-5504', '0378-5505'",'ORAL','ROPINIROLE HYDROCHLORIDE',nan,'134e48b7-a81b-41e5-8214-b6b08f9da998','f5ce07b9-ad0d-4b72-9daf-8662775af093',"'0378-5525-01', '0378-5550-01', '0378-5501-01', '0378-5502-01', '0378-5503-01', '0378-5504-01', '0378-5505-01'",True,nan,nan,nan,'D7ZD41RZI9'
United States,Zebulon,1011 N Arendell Ave,Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.,,"128,704 Inhalers","Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017",20151209,MS and VT,NC,"Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20",20151216,Class II,"GlaxoSmithKline, LLC",D-0519-2016,Letter,72800,20161025,,20151203,27597-2309,Voluntary: Firm initiated,Terminated,,,,,'NDA020983','VENTOLIN','ALBUTEROL SULFATE','GlaxoSmithKline LLC','0173-0682','RESPIRATORY (INHALATION)','ALBUTEROL SULFATE',"'801092', '801095', '859088', '2123076'",'711915f0-e15a-4427-a7ce-b339b49ddb3d','d92c5d6b-ff10-4087-36a2-1cfc464cb967',"'0173-0682-20', '0173-0682-24'",True,nan,nan,nan,'021SEF3731'
United States,Lake Zurich,3 Corporate Dr,Failed Impuities/Degradation Specifications,,"40,280 vials",Lot # 6108831; Exp. 07/16,20160524,Nationwide and Puerto Rico.,IL,"OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-04",20160601,Class II,"Fresenius Kabi USA, LLC",D-0867-2016,Letter,73811,20170123,,20160504,60047-8930,Voluntary: Firm initiated,Terminated,,,,,'ANDA077457','OCTREOTIDE','OCTREOTIDE ACETATE',"'Fresenius Kabi USA, LLC'","'63323-365', '63323-377', '63323-376'","'INTRAVENOUS', 'SUBCUTANEOUS'",'OCTREOTIDE ACETATE',"'312068', '312069', '312070'",'925e3d96-869c-6bdd-e053-2a95a90a1fa6','d6a9a800-889d-417f-b533-1913197d0022',"'63323-365-04', '63323-377-04', '63323-376-04'",True,nan,nan,nan,'75R0U2568I'
United States,Princeton,107 College Rd E,Failed Dissolution Specifications: out of specification results observed for low dissolution.,,"223,650 cartons","Lot #: KB50414, KB50456, Exp 05/17; KB50457, KB50458, KB50459, KB50460, Exp 06/17; KB50580, KB50581, KB50582, KB50583, KB50599, KB50600, Exp 07/17; KB50646, KB50647, KB50721, KB50722, KB50723, KB50724, Exp 09/17; KB50833, KB50834, KB50835, KB50836, KB50837, Exp 10/17; KB50902, KB50903, KB50904, Exp 11/17; KB60037, KB60038, KB60039, KB60040, KB60041, Exp 12/17;  KB60109, KB60110, KB60111, KB60112, KB60113, Exp 01/18; 01KB60249, 01KB60266, 01KB60268, 01KB60269, 01KB60284, Exp 03/18; 01KB60369, 01KB60372, 79KB60368, 79KB60371, Exp 05/18; 79KB60507, 79KB60508, 79KB60509, 79KB60510, 79KB60511, 79KB60512, 79KB60513, 79KB60514, 79KB60515, 79KB60516, Exp 07/18; 79KB60570, 79KB60571, 79KB60585, 79KB60586, Exp 08/18;",20170602,Nationwide in the USA and Puerto Rico,NJ,"Zenatane (isotretinoin) Capsules, USP, 30 mg, 30-count (3 x 10 Prescription Packs) per carton, Rx Only, Manufactured By: Cipla Limited, Kurkumbh Village, Pune 413802 India, Manufactured For: Dr. Reddy's Laboratories, Bachupally 500 090 India, NDC 55111-113-81",20170614,Class II,"Dr. Reddy's Laboratories, Inc.",D-0885-2017,Letter,77353,20181119,,20170522,08540-6623,Voluntary: Firm initiated,Terminated,['Retinoids [CS]'],,,,'ANDA202099','ZENATANE','ISOTRETINOIN',"""Dr. Reddy's Laboratories Limited""","'55111-113', '55111-135', '55111-136', '55111-137'",'ORAL','ISOTRETINOIN',"'197843', '197844', '197845', '403930', '1373333', '1373335', '1373337', '1605088'",'1f5178c1-0f6f-824d-d0ee-1b973377ccc6','27b3cf26-f22e-5b70-1c24-009933b7c6ee',"'55111-135-79', '55111-135-81', '55111-136-79', '55111-136-81', '55111-137-79', '55111-137-81', '55111-113-79', '55111-113-81', '55111-113-78'",True,nan,"'N0000175607', 'M0018962'",'Retinoid EPC','EH28UP18IF'
United States,Bronx,1700 Bathgate Ave,Failed Degradation/Impurities Specifications: Out of specification related substance results during stability testing.,,12252 bottles,"Lot #: 7DT0280, 7ET0565, Exp. 02/19",20190220,Nationwide within the United States,NY,"Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, NY 10457 Distributed by Perrigo Allegan, MI 49010, 45802-401-09",20190227,Class III,"Perrigo New York, Inc.",D-0512-2019,Letter,82127,,,20190213,10457-7512,Voluntary: Firm initiated,Ongoing,,['Protein Synthesis Inhibitors [MoA]'],"['Decreased DNA Replication [PE]', 'Decreased Protein Synthesis [PE]', 'Decreased RNA Replication [PE]']",,'ANDA078594','CICLOPIROX','CICLOPIROX','Perrigo New York Inc','45802-401','TOPICAL','CICLOPIROX','250344','e3ad112c-6dfb-4f7b-a643-c3dfe975ca05','c3722d52-407c-499b-a08b-b299609f203c','45802-401-09',True,nan,"'N0000008577', 'N0000008841', 'N0000008853', 'N0000000150'",nan,'19W019ZDRJ'
United States,Princeton,100 College Rd W,Labeling: Incorrect or missing package insert.,,"76,644 bottles","Lot #s: 289210F, Exp. 10/31/2019; 290632F, Exp. 10/31/2020",20191028,Nationwide in the U.S.,NJ,"Gatifloxacin Ophthalmic Solution 0.5%, For Use in the Eyes Only, Rx Only, Sterile, 2.5 mL bottle, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540, Product of India, NDC 61314-672-25.",20191106,Class III,Sandoz Inc,D-0163-2020,Letter,84082,,,20191017,08540-6604,Voluntary: Firm initiated,Ongoing,,,,,'ANDA204227','GATIFLOXACIN','GATIFLOXACIN','Sandoz Inc','61314-672','OPHTHALMIC','GATIFLOXACIN','992395','855a6b70-9e06-4c8e-8d6f-f96ce8dbba12','9e6fcd14-1fee-493f-811c-e18cbfbee65b','61314-672-25',True,nan,nan,nan,'L4618BD7KJ'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"56,405 bottles","Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-429-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Princeton,107 College Rd E,Subpotent drug,,,"Lot #: a) C401537, Exp 07/2015; b) C401539, Exp 07/2015",20150618,Nationwide,NJ,"Amlodipine besylate and Atorvastatin calcium tablets, 10mg/10mg, packaged in a)30-count bottle (NDC 43598-321-30), b) 90-count bottle (NDC 43598-321-90), Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Bachupally, 500 090 India",20150624,Class III,"Dr. Reddy's Laboratories, Inc.",D-1144-2015,Letter,71375,20160331,,20150506,08540-6623,Voluntary: Firm initiated,Terminated,,,,,'ANDA203874','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM',"""Dr. Reddy's Laboratories Inc""","'43598-313', '43598-323', '43598-320', '43598-317', '43598-322', '43598-319', '43598-316', '43598-314', '43598-321', '43598-318', '43598-315'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'54058ac6-94e2-d2d3-5c46-886b3478fc76','abee4a34-89cc-d886-192c-32582ab8f024',"'43598-323-30', '43598-323-60', '43598-323-90', '43598-323-05', '43598-320-30', '43598-320-60', '43598-320-90', '43598-320-05', '43598-317-30', '43598-317-60', '43598-317-90', '43598-317-05', '43598-322-30', '43598-322-60', '43598-322-90', '43598-322-05', '43598-319-30', '43598-319-60', '43598-319-90', '43598-319-05', '43598-316-30', '43598-316-60', '43598-316-90', '43598-316-05', '43598-314-30', '43598-314-60', '43598-314-90', '43598-314-05', '43598-321-30', '43598-321-60', '43598-321-90', '43598-321-05', '43598-318-30', '43598-318-60', '43598-318-90', '43598-318-05', '43598-315-30', '43598-315-60', '43598-315-90', '43598-315-05', '43598-313-30', '43598-313-60', '43598-313-90', '43598-313-05'",True,"'0343598323305', '0343598315300', '0343598320304', '0343598317304', '0343598313306', '0343598322308', '0343598319308', '0343598316307', '0343598314303'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Lake Forest,275 N Field Dr,"The affected lots of Carboplatin Injection, Cytarabine  Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.",,"131,264 vials","lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013",20120919,"Nationwide, including Puerto Rico and Guam.    Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and  Vietnam",IL,"Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50",20120926,Class II,Hospira Inc.,D-1682-2012,Letter,62459,20161215,,20120627,60045-2579,Voluntary: Firm initiated,Terminated,,,['Microtubule Inhibition [PE]'],,'ANDA076131','PACLITAXEL','PACLITAXEL',"'Hospira, Inc.'",'61703-342','INTRAVENOUS','PACLITAXEL','312199','7df7341d-96a8-49cb-8443-dcdcead85790','ea28753a-8631-460a-bfdc-b101eb8ac84a',"'61703-342-09', '61703-342-22', '61703-342-50'",True,nan,"'N0000175085', 'N0000175592'",'Microtubule Inhibitor EPC','P88XT4IS4D'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,"12,609 vials","Lot # 31326456B, exp. date 02/28/2021",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA  19454, NDC 0703-1995-01.",20210303,Class II,Teva Pharmaceuticals USA,D-0280-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,,,,'ANDA078396','EPOPROSTENOL SODIUM','EPOPROSTENOL SODIUM',"'Teva Parenteral Medicines, Inc.'","'0703-1985', '0703-1995', '0703-9258'",'INTRAVENOUS','EPOPROSTENOL SODIUM',"'562501', '562502'",'1916c211-a026-4b81-9909-35962a9ae003','56733651-d331-4e69-a6a3-303756ccc53c',"'0703-1985-01', '0703-1995-01', '0703-9258-01', '0703-9258-09'",True,"'0307031985017', '0307031995016'",nan,nan,"'4K04IQ1OF4', '059QF0KO0R'"
United States,Orlando,4190 Millenia Blvd,Crystallization: Presence of particulate matter identified as API crystallization,,16485 vials,"Lot#: 18048, 18049 Exp. 04/2020; 18050 Exp 05/2020; 19036 Exp 12/2020",20191017,U.S.A. Nationwide,FL,"Leucovorin Calcium Injection, USP 500 mg*/50 mL (10 mg/mL) 50 mL Single-Dose Vial NDC 50742-464-50 Rx Only Ingenus Pharmaceuticals, LLC. Orlando, FL 32839",20191023,Class II,Ingenus Pharmaceuticals Llc,D-0146-2020,Letter,84011,20201201,,20191009,32839-6408,Voluntary: Firm initiated,Terminated,,,,,'ANDA210917','LEUCOVORIN CALCIUM','LEUCOVORIN CALCIUM',"'Ingenus Pharmaceuticals, LLC'",'50742-464',"'INTRAMUSCULAR', 'INTRAVENOUS'",'LEUCOVORIN CALCIUM','2104714','d9406087-7998-4b5d-a887-5915015c756c','8c354d53-1ab3-4c6a-bd84-b9642edc3477','50742-464-50',True,'0350742464500',nan,nan,'RPR1R4C0P4'
United States,Bridgewater,400 Somerset Corporate Blvd,Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.,,"205,853 bottles",VASOTEC 2.5MG TAB 30CT  12K015P  exp.  9/30/2014      VASOTEC 2.5MG TAB 30CT  13G048P   exp.  07/31/2015    VASOTEC 2.5MG TAB 30CT  14A065P   exp. 07/31/2015    VASOTEC 2.5MG TAB 90CT  13G020P   exp. 07/31/2015      VASOTEC 2.5MG TAB 90CT   12K020P  exp.  9/30/2014      VASOTEC 2.5MG TAB 90CT  13B016P   exp. 9/30/2014      VASOTEC 5MG TAB 30CT   13B022P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT 13B023P   exp. 2/28/2015    VASOTEC 5MG TAB 30CT  13C015P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT  13E002P   exp. 02/28/2015    VASOTEC 5MG TAB 30CT 14A002P   exp.    11/30/2015    VASOTEC 5MG TAB 30CT  13L066P   exp. 11/30/2015    VASOTEC 5MG TAB 90CT   13B018P   exp. 2/28/2015      VASOTEC 5MG TAB 90CT  13G015P   exp. 06/30/2015      VASOTEC 10MG TAB 90CT   12M017P   exp. 11/30/2014    VASOTEC 10MG TAB 1000CT   12L105P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT   12M016P   exp. 11/30/2014      VASOTEC 10MG TAB 30CT  13G013P   exp. 06/30/2015    VASOTEC 10MG TAB 30CT  13J081P  exp. 9/30/2015    VASOTEC 10MG TAB 90CT 12M025P   exp. 11/30/2014    VASOTEC 10MG TAB 90CT  13J082P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J085P   exp. 0/2015    VASOTEC 10MG TAB 90CT  13J094P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13J098P   exp. 09/30/2015    VASOTEC 10MG TAB 1000CT  13G011P   exp. 06/30/2015    VASOTEC 10MG TAB 1000CT  13J097P   exp. 09/30/2015    VASOTEC 20MG TAB 30CT   12J017P   exp. 5/31/2014    VASOTEC 20MG TAB 30CT   13C016P   exp. 2/28/2015    VASOTEC 20MG TAB 30CT  13E003P   exp. 02/28/2015    VASOTEC 20MG TAB 30CT  13L068P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J086P   exp. 09/30/2015    VASOTEC 20MG TAB 90CT  13J087P   exp. 09/30/2015      VASOTEC 20MG TAB 90CT   12M029P   exp. 11/30/2014    VASOTEC 20MG TAB 90CT   12M030P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT   12J023P   exp. 5/31/2014    VASOTEC 20MG TAB 1000CT  12L108P   exp. 11/30/2014    VASOTEC 20MG TAB 1000CT  13C088P   exp. 02/28/2015    VASOTEC 20MG TAB 1000CT  13J099P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M054P   exp. 09/30/2015    VASOTEC 20MG TAB 1000CT  13M055P   exp. 12/31/2015    VASOTEC 20MG TAB 1000CT  14B054P   exp. 12/31/2015,20141010,Nationwide,NJ,"Vasotec (enalapril maleate) tablets, RX only, Manufactured by Valeant Pharmaceuticals International, Inc., Steinbach, MD R5G 1Z7 Canada    2.5 mg  90 ct -  NDC 0187-0140-90    5 mg 30 ct - NDC  0187-0141-30    5 mg 90 ct - NDC 0187-0141-90    10 mg 30 ct - NDC 0187-0142-30    10 mg 90 ct - NDC 0187-0142-90    10 mg  1000 ct - NDC 0187-0142-10      20 mg 30 ct - NDC 0187-0143-30    20 mg 90 ct - NDC 0187-0143-90     20 mg 1000 ct - NDC 0187-0143-10          NDC #'s 64455-140, 64455-141, 64455-142 and 64455-143, 30 ct. bottles, 90 ct. bottles and 1000 ct. bottles",20141022,Class III,Valeant Pharmaceuticals North America LLC,D-0019-2015,Letter,68572,20150804,,20140521,08807,Voluntary: Firm initiated,Terminated,,,,,'NDA018998','VASOTEC','ENALAPRIL MALEATE','Bausch Health US LLC',"'0187-0140', '0187-0141', '0187-0142', '0187-0143'",'ORAL','ENALAPRIL MALEATE',"'858804', '858806', '858810', '858812', '858813', '858815', '858817', '858819'",'18a458cc-976a-4019-bd85-18f55a224f45','39631f1f-5d19-43c1-b504-bf56d991ed97',"'0187-0140-30', '0187-0140-90', '0187-0141-30', '0187-0141-90', '0187-0141-10', '0187-0142-30', '0187-0142-90', '0187-0142-10', '0187-0143-30', '0187-0143-90', '0187-0143-10'",True,nan,nan,nan,'9O25354EPJ'
United States,Hauppauge,"Suite # 401, 4th Floor",CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.,"Room No. 430, 150 Motor Parkway","52,549,000 tablets","Lot #: Lot #: HM6067, HM6068, HM6069, HM6070, HM6072, HM6072, HM6073, HM6074, HM6075, HM6076, HM6077, HM6078, HM6079, HM6080, HM6081, HM6082, HM6083, HM6084, HM6085, HM6086, HM6087, HM6088, HM6089, HM6090, HM6091, HM6092, HM6093, HM6094, HM6095, HM6096, Exp 02/18; HM6097, HM6098, HM6099, Exp 03/18; HM6100, HM6101, HM6102, HM6103, HM6104, HM6105, HM6106, HM6107, HM6108, HM6109, HM6110, HM6111, HM6112, HM6113, HM6114, HM6115, HM6116, HM6117, HM6118, HM6119, HM6120, HM6121, HM6122, HM6123, HM6124, HM6125, HM6126, HM6127, HM6128, HM6129, HM6130, HM6131, HM6132, Exp 08/18; HM6133, HM6134, HM6135, HM6136, HM6137, HM6128, HM6139; Exp 09/18",20180124,Distributed to repackaging firms in NY who then distributed Nationwide in the USA.,NY,"Ibuprofen Tablets, USP 800 mg, 6 x 1900 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-123-27.",20180131,Class II,Marksans Pharma Inc.,D-0240-2018,Letter,78822,20200526,,20180109,11788,Voluntary: Firm initiated,Terminated,"['Anti-Inflammatory Agents, Non-Steroidal [CS]']",['Cyclooxygenase Inhibitors [MoA]'],,,'ANDA090796','IBUPROFEN','IBUPROFEN','MARKSANS PHARMA LIMITED',"'25000-121', '25000-122', '25000-123'",'ORAL','IBUPROFEN',"'197805', '197806', '197807'",'a838f8d6-e1db-481a-8fd5-0731bda8f675','e54209c2-f726-440b-ac60-5a72710d2a9b',"'25000-121-03', '25000-121-12', '25000-121-19', '25000-121-29', '25000-121-98', '25000-121-93', '25000-122-03', '25000-122-12', '25000-122-18', '25000-122-28', '25000-122-98', '25000-122-93', '25000-123-03', '25000-123-12', '25000-123-17', '25000-123-27', '25000-123-98', '25000-123-93'",True,"'0325000122126', '0325000123123', '0325000121129'","'N0000000160', 'M0001335', 'N0000175722'",'Nonsteroidal Anti-inflammatory Drug EPC','WK2XYI10QM'
United States,Bristol,501 5th Street,Subpotent Drug: The products were below specification for potency at the expiry stability point.,,"33,227 bottles","Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13",20130520,Nationwide and Puerto Rico,TN,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",20130529,Class II,"King Legacy, a wholly owned subsidiary of Pfizer",D-431-2013,Letter,65172,20160630,,20130430,37620-2304,Voluntary: Firm Initiated,Terminated,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,New York,235 E 42nd St,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.",,141 bottles,"Lot #: CY0937, Exp 12/2021",20200213,Nationwide in the USA.,NY,"Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.",20200219,Class II,Pfizer Inc.,D-0841-2020,Letter,84860,20210308,,20200205,10017-5703,Voluntary: Firm initiated,Terminated,,,,,'NDA021540','CADUET','AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM','Pfizer Laboratories Div Pfizer Inc',"'0069-2150', '0069-2960', '0069-2970', '0069-2980', '0069-2170', '0069-2190', '0069-2260', '0069-2160', '0069-2180', '0069-2250', '0069-2270'",'ORAL',"'AMLODIPINE BESYLATE', 'ATORVASTATIN CALCIUM TRIHYDRATE'",nan,'3d5d43cd-1ae9-4eb2-8351-cde522a3d397','6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6',"'0069-2960-30', '0069-2970-30', '0069-2980-30', '0069-2150-30', '0069-2170-30', '0069-2190-30', '0069-2260-30', '0069-2160-30', '0069-2180-30', '0069-2250-30', '0069-2270-30'",True,"'0300692960300', '0300692970309', '0300692170303', '0300692160304', '0300692260301', '0300692150305', '0300692190301', '0300692250302', '0300692270300'",nan,nan,"'48A5M73Z4Q', '864V2Q084H'"
United States,Salisbury,207 Kiley Dr,Presence of Foreign Substance: Presence of a foreign object in a single tablet.,,"1,824 bottles","Lot #: NT119005A, Exp 07/2021",20191206,Nationwide in the USA.,MD,"Amantadine Hydrochloride Tablets, 100 mg, 100-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA; NDC 59746-699-01.",20191218,Class II,"Jubilant Cadista Pharmaceuticals, Inc.",D-0576-2020,Letter,84396,,,20191202,21801-2249,Voluntary: Firm initiated,Ongoing,,,,,'ANDA210403','AMANTADINE HYDROCHLORIDE','AMANTADINE HYDROCHLORIDE','Jubilant Cadista Pharmaceuticals Inc.','59746-699','ORAL','AMANTADINE HYDROCHLORIDE','849395','8743abcd-9667-46e1-b60c-997b6f4238f2','132aa4fd-1880-4165-2b72-fe650b1c7856',"'59746-699-30', '59746-699-01', '59746-699-05'",True,'0359746699017',nan,nan,'M6Q1EO9TD0'
United States,New York,235 East 42nd Street,Chemical contamination: emission of strong odor after package was opened.,,37809 bottles,"Lot # a)  66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14",20130418,Nationwide and PR,NY,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",20130424,Class II,Pfizer Inc.,D-253-2013,Letter,64835,,,20130328,10017-5703,Voluntary: Firm initiated,Ongoing,,,,,'NDA021301','LEVOXYL','LEVOTHYROXINE SODIUM','Pfizer Laboratories Div Pfizer Inc',"'60793-850', '60793-851', '60793-852', '60793-853', '60793-854', '60793-855', '60793-856', '60793-857', '60793-858', '60793-859', '60793-860'",'ORAL','LEVOTHYROXINE SODIUM',"'892246', '892251', '966157', '966164', '966170', '966175', '966184', '966190', '966194', '966200', '966204', '966211', '966220', '966221', '966222', '966224', '966225', '966248', '966249', '966253', '966270', '966283'",'e230c170-2a16-47d0-bce7-ac0414c192f7','758588c3-c63e-491b-0aa2-4f50d80cb174',"'60793-850-10', '60793-850-01', '60793-851-10', '60793-851-01', '60793-852-10', '60793-852-01', '60793-853-10', '60793-853-01', '60793-854-10', '60793-854-01', '60793-855-10', '60793-855-01', '60793-856-10', '60793-856-01', '60793-857-10', '60793-857-01', '60793-858-10', '60793-858-01', '60793-859-10', '60793-859-01', '60793-860-10', '60793-860-01'",True,"'0360793856018', '0360793850016', '0360793852010', '0360793851013', '0360793857015', '0360793853017', '0360793854014', '0360793858012', '0360793855011', '0360793859019', '0360793860015'",nan,nan,'9J765S329G'
United States,Saint Louis,4041 Forest Park Ave,Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.,,83 boxes,"Lot #: M086920 and M098260, Exp. 08/2013",20130719,Nationwide and Military and Government Consignees,MO,"Mitosol (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use (NDC 49771-002-01), 3 kits per box (NDC 49771-002-03), Rx only, Manufactured for: Mobius Therapeutics, LLC, 4041 Forest Park Avenue, St. Louis, MO  63108 USA.",20130731,Class I,Mobius Therapeutics LLC,D-809-2013,Telephone,64018,20130729,,20130103,63108-3213,Voluntary: Firm initiated,Terminated,,,,,'NDA022572','MITOSOL','MITOMYCIN','Mobius Therapeutics LLC','49771-002',nan,nan,"'1244553', '1244558'",'c6a6ba20-293d-4663-a3ec-9a20cf78bf59','244002c6-c61d-43fe-9326-072797113979',"'49771-002-01', '49771-002-03'",True,nan,nan,nan,nan
United States,Columbus,2550 John Glenn Ave Ste A,Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.,,"a) 15,409 bottles b) 5,128 bottles","Lot #: a)  M601509, Exp 3/31/2018; M606506, Exp 4/30/2018; b) M601510, Exp 3/31/2018;  M604444, Exp 4/30/2018; M606515, Exp 4/30/2018.",20161116,Nationwide and Puerto Rico,OH,"Bupropion Hydrochloride Extended-Release Tablets, USP  (XL), 300 mg, a) 90-count bottle (NDC 68001-264-05),  b) 500-count bottle (NDC 68001-264-03) , Rx only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India  For BluePoint Laboratories",20161123,Class III,Amerisource Health Services,D-0137-2017,Letter,75581,20170629,,20161027,43217-1188,Voluntary: Firm initiated,Terminated,,,,,'ANDA201567','BUPROPION','BUPROPION','BluePoint Laboratories','68001-264','ORAL','BUPROPION HYDROCHLORIDE','993557','688cfb04-0f6b-4e42-be01-b0e4c33b1402','1622e085-a565-4b48-89d5-2fb06a032b75',"'68001-264-04', '68001-264-05', '68001-264-03'",True,'0368001264044',nan,nan,'ZG7E5POY8O'
United States,Princeton,506 Carnegie Ctr Ste 400,Failed Impurities/Degradation Specifications:Out of specification result for a known impurity obtained during testing.,,,"Lot #:  EN0389, EP0473, Exp. 8/2016 ; FA4834, FN2602, Exp. 2/2017; FW3646 , Exp.11/2017",20160620,Nationwide,NJ,"Dicloxacillin Sodium Capsules USP, 500mg, Rx Only, 100 Capsule bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz  Inc. , Princeton, NJ 08540, Product of Spain, NDC 0781-2258-01",20160629,Class III,"Sandoz, Inc",D-1046-2016,Letter,74068,20170817,,20160502,08540-6243,Voluntary: Firm initiated,Terminated,,,,,'ANDA061454','DICLOXACILLIN SODIUM','DICLOXACILLIN SODIUM','Sandoz Inc',"'0781-2248', '0781-2258'",'ORAL','DICLOXACILLIN SODIUM',"'197595', '197596'",'040ad2d4-da0b-43bc-bb30-3a4b64245c90','65c3e99b-ec77-416c-ad70-596d6f0a9c31',"'0781-2248-01', '0781-2258-01'",True,"'0307812258019', '0307812248010'",nan,nan,'4HZT2V9KX0'
United States,Parsippany,400 Interpace Pkwy,Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.,,50 vials,"Lot # 31326582B, exp. date 02/2022;  Lot # 31326964B, exp. date 04/2022",20210221,Product was distributed nationwide in the USA and Puerto Rico.,NJ,"Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA  19454.",20210303,Class II,Teva Pharmaceuticals USA,D-0271-2021,Letter,87298,,,20210210,07054-1120,Voluntary: Firm initiated,Ongoing,,['Alkylating Activity [MoA]'],,,'ANDA075259','DACARBAZINE','DACARBAZINE',"'Teva Parenteral Medicines, Inc.'",'0703-5075','INTRAVENOUS','DACARBAZINE','1731338','83fa961b-7275-4e85-9047-e956c63316da','26e91082-7698-4680-beab-07c47802f0f9',"'0703-5075-01', '0703-5075-03'",True,'0307035075011',"'N0000000236', 'N0000175558'",'Alkylating Drug EPC','7GR28W0FJI'
United States,Oklahoma City,727 N Ann Arbor Ave,Failed Impurities/Degradation Specifications:Out of specification results for individual unknown impurities at 30th month Room Temperature Retained Sample stabilities test .,,3440 bottles,"Lots: a) H15E22, Exp. 8/31/17; J15E02, Exp. 10/31/17. b) J15A53, Exp. 10/31/17; D16C78, Exp.12/31/17; c)J15D54, Exp. 10/31/17; d)H15B60, Exp. 8/31/17; e) J15A49, Exp. 10/31/17; C16A14, Exp. 12/31/17.",20170823,Nationwide.,OK,"Phentermine Capsules, 15 mg,  a) 7-count bottle (NDC 55289-791-07), b) 14-count bottle ( NDC 55289-791-14), c) 21-count bottle (NDC 55289-791-21), d) 30-count bottle (NDC 55289-791-30), e) 60-count bottle (NDC 55289-791-60), Packaged by PD-Rx Pharmaceuticals, Incorporated, Oklahoma City, OK. 73127 Mfg: KVK-Tech, Inc. Newtown, PA 18940",20170830,Class III,"PD-Rx Pharmaceuticals, Inc.",D-1118-2017,Letter,77915,20200129,,20170811,73127-5822,Voluntary: Firm initiated,Terminated,,,,['10702-026'],'ANDA040886','PHENTERMINE HYDROCHLORIDE','PHENTERMINE HYDROCHLORIDE',"'PD-Rx Pharmaceuticals, Inc.'",'55289-791','ORAL','PHENTERMINE HYDROCHLORIDE','968766','adb95e34-aeaf-2f78-e053-2995a90a643a','4000c00f-aa6c-4ea5-af0e-149dde3c74db',"'55289-791-07', '55289-791-14', '55289-791-15', '55289-791-21', '55289-791-28', '55289-791-30', '55289-791-60'",nan,'0355289791140',nan,nan,'0K2I505OTV'
Canada,Cambridge,25 Wolseley Court,"Subpotent Drug; Two lots of Lidocaine 2% with Epinephrine 1:100,000 Injectable, distributed under the names: Octocaine 100, and 2% Xylocaine Dental, may be subpotent for the epinephrine component.",,"12,497 Boxes","Lot #s: D00290 D, Exp 08/2013; D00205 A, Exp 11/2013",20130826,Nationwide and Canada,,"Lidocaine Hydrochloride 2% and Epinephrine 1:100,000 Injection, Rx Only, For Dental Block and Infiltration Only, 50 Cartridges per box - 1.7 mL minimum each,  NDC #s: a) Octocaine 100, Mfr'ed for Septodont, Louisville, CO, 80027, by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3, 0362-9023-05; b) Superdent, Dist by: Darby Dental Supply Co., Jericho, NY 11753, Made in Canada,  66467-9730-5; and c) Dist by: IQ Dental, 353 Rt 46 W, Bldg C Unit 120, Fairfield, NJ, 07004, made in Canada, 42756-1030-5; Manufactured by: by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada N1R6X3.",20130904,Class II,Novocol Pharmaceutical of Canada,D-923-2013,E-Mail,65979,20140107,,20130814,,Voluntary: Firm initiated,Terminated,,,,,'ANDA088390',"'LIDOCAINE', 'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE'",'LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE',"'Darby Dental Supply, LLC', 'IQ Dental'","'66467-9730', '42756-1030'",'SUBCUTANEOUS',"'LIDOCAINE HYDROCHLORIDE', 'EPINEPHRINE BITARTRATE'",'1293648',"'da0ce9ff-2758-49ea-96e6-2890a62bf7e2', '4b173661-7764-46dc-81f7-1112ba3e2379'","'e5ed4c2a-e320-48cf-a2fd-61d48481c624', 'b1b09a84-7978-4380-9c40-a4bf837be637'","'66467-9730-5', '42756-1030-5', '0362-9023-05'",True,nan,nan,nan,"'V13007Z41A', '30Q7KI53AK'"
United States,Lake Forest,275 N Field Dr,Presence of particulate matter: A returned customer sample was evaluated and found to have human hair attached to a pinched area of the stopper.,,"100,100 units","Lot# 40-316-DK, Exp 01APR2016",20150213,Nationwide,IL,"1% LIDOCAINE HCl Injection, USP, 10 mg/mL, 30 mL Single-dose, Preservative-Free glass vial (Twenty-five (25) units per box/fifty (50) units per case, NDC 0409-4279-02, Hospira, Inc., Lake Forest, IL 60045",20150225,Class I,Hospira Inc.,D-0391-2015,Letter,69567,20151229,,20141016,60045-2579,Voluntary: Firm Initiated,Terminated,,,,,'ANDA088325','LIDOCAINE HYDROCHLORIDE','LIDOCAINE HYDROCHLORIDE',"'Hospira, Inc.'","'0409-4275', '0409-4713', '0409-4278', '0409-4279', '0409-4776', '0409-4282', '0409-4277', '0409-4276'","'INFILTRATION', 'PERINEURAL'",'LIDOCAINE HYDROCHLORIDE',"'1010033', '1010671', '1010900', '1737343', '1737562', '1737566', '1737568', '1737636', '1737757', '1737763'",'07591815-286b-4afc-87b8-bc644a374827','3b2dd84e-cee8-4e58-d494-395a65a353a0',"'0409-4713-12', '0409-4713-26', '0409-4713-02', '0409-4713-72', '0409-4713-62', '0409-4713-75', '0409-4713-65', '0409-4713-42', '0409-4713-25', '0409-4713-32', '0409-4278-16', '0409-4278-01', '0409-4279-16', '0409-4279-02', '0409-4776-10', '0409-4776-01', '0409-4282-11', '0409-4282-25', '0409-4282-01', '0409-4282-12', '0409-4282-02', '0409-4277-16', '0409-4277-01', '0409-4277-17', '0409-4277-02', '0409-4276-16', '0409-4276-01', '0409-4276-17', '0409-4276-02', '0409-4275-16', '0409-4275-01'",True,nan,nan,nan,'V13007Z41A'
United States,Salisbury,207 Kiley Dr,Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.,,744 bottles,"Lot # 17P0430, Exp 05/19",20171116,Nationwide,MD,"Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06",20171122,Class III,"Jubilant Cadista Pharmaceuticals, Inc.",D-0082-2018,Letter,78461,20200212,,20171030,21801-2249,Voluntary: Firm initiated,Terminated,,,,,'ANDA040659','MECLIZINE HYDROCHLORIDE','MECLIZINE HYDROCLORIDE','JUBILANT CADISTA PHARMACEUTICALS INC.',"'59746-121', '59746-122'",'ORAL','MECLIZINE HYDROCHLORIDE',"'995624', '995666'",'9fbce799-a4af-48b2-95c8-4f5bcb5a5833','9350fefc-9c00-182c-c3a9-044d4a40856f',"'59746-122-06', '59746-122-10', '59746-121-06', '59746-121-10'",True,"'0359746121068', '0359746122065'",nan,nan,'HDP7W44CIO'
United States,Aquebogue,311 W Ln,Lack of Assurance of Sterility,PO Box 849,,16260 9/19  17303 10/20  18032 2/21  18235 9/21  18285 11/21  19021 1/22,20191115,U.S.A. Nationwide,NY,"Ocusoft Goniosoft Hypromellose 2.5% Opthalmic Demulcent Solution, 15 mL, Manufactured for: Ocusoft, Inc., Richmond, TX 77406-0429, NDC 54799-503-15",20191127,Class II,"Altaire Pharmaceuticals, Inc.",D-0397-2020,"Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",83265,,,20190702,11931-0849,Voluntary: Firm initiated,Ongoing,,,,,nan,'GONIOSOFT','HYPROMELLOSE 2.5%',"'OCuSOFT, Inc.'",'54799-503','OPHTHALMIC','HYPROMELLOSES',"'206638', '310934'",'6a367c59-f113-454e-97ae-bd404cd3d32e','b9885de2-bd4c-c5c8-7ce3-c3f1669e74ea','54799-503-15',True,'0354799503151',nan,nan,'3NXW29V3WO'
United States,Parsippany,20 Waterview Blvd Ste 3,Failed Tablet/Capsule Specifications: out of specification for thickness.,,"93,393 bottles","Lot #s: a) LM10525, Exp 03/15; LM10727, Exp 04/15; LM11519, Exp 08/15; LN10008, Exp 11/15;  LN10121, Exp 12/15; LN10887, Exp 04/16; LM11248, Exp 06/16  Lot #s: b) LM10522, Exp 03/15; LM10726, Exp 04/15; LN10007, Exp 11/15; LN10116, Exp 12/15; LN10888, Exp 04/16; LN11281 Exp 07/16",20150501,Nationwide,NJ,"Captopril Tablets, USP 12.5 mg, Rx Only, a) 100 count bottles NDC 64679-902-01, b) 1000 count bottles NDC 64679-902-02, Manufactured by Wockhardt Limited, Mumbai, India, Distributed by: Wockhardt USA LLC., 20 Waterview Boulevard, Parsippany, NJ 07054 USA",20150513,Class II,Wockhardt Usa Inc.,D-0975-2015,Letter,70740,20171214,,20150312,07054-1271,Voluntary: Firm initiated,Terminated,,['Angiotensin-converting Enzyme Inhibitors [MoA]'],,,'ANDA074532','CAPTOPRIL','CAPTOPRIL','Wockhardt USA LLC.',"'64679-902', '64679-903', '64679-904', '64679-905'",'ORAL','CAPTOPRIL',"'308962', '308963', '308964', '317173'",'7497d288-2502-4623-8bb8-17c6e20cc6f7','4a3e016f-8c88-4041-9a56-0090b0cd170a',"'64679-902-01', '64679-902-02', '64679-902-05', '64679-903-01', '64679-903-02', '64679-903-05', '64679-904-01', '64679-904-02', '64679-904-05', '64679-905-01', '64679-905-04'",True,"'0364679902011', '0364679903025', '0364679904015', '0364679905012'","'N0000175562', 'N0000000181'",'Angiotensin Converting Enzyme Inhibitor EPC','9G64RSX1XD'
United States,Newark,587 Old Baltimore Pike,"Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.",,"40,368 bottles","Lot # JB5047, Exp 10/19",20170711,Nationwide in the USA and Puerto Rico to physician offices.,DE,"BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.",20170719,Class I,"AstraZeneca Pharmaceuticals, LP",D-0958-2017,Press Release,77336,20180424,,20170525,19702-1307,Voluntary: Firm initiated,Terminated,,"['Phenylalanine Hydroxylase Activators [MoA]', 'P2Y12 Receptor Antagonists [MoA]', 'Cytochrome P450 3A4 Inhibitors [MoA]', 'Cytochrome P450 3A5 Inhibitors [MoA]', 'P-Glycoprotein Inhibitors [MoA]']",['Decreased Platelet Aggregation [PE]'],,'NDA022433','BRILINTA','TICAGRELOR','AstraZeneca Pharmaceuticals LP',"'0186-0776', '0186-0777'",'ORAL','TICAGRELOR',"'1116635', '1116639', '1666332', '1666334'",'9bce28b4-a64e-4f70-8838-26ffea77b72d','f7b3f443-e83d-4bf2-0e96-023448fed9a8',"'0186-0777-08', '0186-0777-60', '0186-0777-18', '0186-0777-39', '0186-0777-28', '0186-0776-60', '0186-0776-94'",True,nan,"'N0000182142', 'N0000190482', 'N0000008832', 'N0000182143', 'N0000182141', 'N0000190115', 'N0000185503'",'P2Y12 Platelet Inhibitor EPC','GLH0314RVC'
